MCID: GNT003
MIFTS: 54

Genital Herpes

Categories: Immune diseases, Infectious diseases, Reproductive diseases

Aliases & Classifications for Genital Herpes

MalaCards integrated aliases for Genital Herpes:

Name: Genital Herpes 12 54 42 3 15 62 17 71
Herpes Genitalis 12 43
Genital Herpes Simplex 12
Virus-Genital Herpes 12
Venereal Herpes 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8704
ICD9CM 34 054.1
MeSH 43 D006558
NCIt 49 C14364
SNOMED-CT 67 33839006
UMLS 71 C0019342

Summaries for Genital Herpes

MedlinePlus : 42 Genital herpes is a sexually transmitted disease (STD) caused by a herpes simplex virus (HSV). It can cause sores on your genital or rectal area, buttocks, and thighs. You can get it from having vaginal, anal, or oral sex with someone who has it. The virus can spread even when sores are not present. Mothers can also infect their babies during childbirth. Symptoms of herpes are called outbreaks. You usually get sores near the area where the virus has entered the body. The sores are blisters which break and become painful, and then heal. Sometimes people do not know they have herpes because they have no symptoms or very mild symptoms. The virus can be more serious in newborn babies or in people with weak immune systems. Repeat outbreaks are common, especially during the first year. Over time, you get them less often and the symptoms become milder. The virus stays in your body for life. There are tests that can diagnose genital herpes. There is no cure. However, medicines can help lessen symptoms, decrease outbreaks, and lower the risk of passing the virus to others. Correct usage of latex condoms can reduce, but not eliminate, the risk of catching or spreading herpes. The most reliable way to avoid infection is to not have anal, vaginal, or oral sex.

MalaCards based summary : Genital Herpes, also known as herpes genitalis, is related to herpes simplex and chlamydia, and has symptoms including fever, sores and swollen glands. An important gene associated with Genital Herpes is ACKR1 (Atypical Chemokine Receptor 1 (Duffy Blood Group)), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Famciclovir and Metronidazole have been mentioned in the context of this disorder. Affiliated tissues include genital system, rectum and testes, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A herpes simplex that results in infection located in genital system, or located in rectum, has material basis in Human herpesvirus 1 or has material basis in Human herpesvirus 2, which is transmitted by sexual contact. The infection has symptom sores, has symptom fever, and has symptom swollen glands.

CDC : 3 Genital herpes is a common sexually transmitted disease (STD) that any sexually active person can get. Most people with the virus don't have symptoms. Even without signs of the disease, herpes can still be spread to sex partners.

Wikipedia : 74 Genital herpes is an infection by the herpes simplex virus (HSV) of the genitals. Most people either... more...

Related Diseases for Genital Herpes

Diseases related to Genital Herpes via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 445, show less)
# Related Disease Score Top Affiliating Genes
1 herpes simplex 31.7 TNFRSF14 TLR2 NECTIN1 IFI16 GYPC CD8A
2 chlamydia 30.9 TLR2 IL4 IL18 IL10
3 syphilis 30.7 CD8A CD4 CCR6
4 meningitis 30.7 TLR2 IL4 IL18 IL10 CCL5
5 encephalitis 30.6 TLR2 IL4 IL10 CCL5
6 cervicitis 30.5 TLR2 CD8A CD4
7 cryptococcal meningitis 30.5 CD8A CD4 CCR6
8 candidiasis 30.5 TLR2 IL4 IL10 CCR6
9 oral candidiasis 30.4 CD8A CD4 CCR6
10 dermatitis 30.4 IL4 IL18 IL10 CCR6
11 acquired immunodeficiency syndrome 30.4 IL10 CD4 CCR6 APOE
12 toxoplasmosis 30.4 TLR2 IL4 IL10
13 bacterial vaginosis 30.4 TLR2 PI3 IL4 IL10
14 stomatitis 30.3 IL4 IL10 CD4
15 filariasis 30.2 TLR2 IL10 CCL5
16 lichen planus 30.2 TLR2 IL4 IL10 CCL5
17 neuritis 30.1 IL4 IL10 CCL5 APOE
18 scabies 30.1 IL10 CD4 CCR6
19 myocarditis 30.0 IL4 IL18 IL10 CD80
20 keratitis, hereditary 29.9 TLR2 CD4 CCR6
21 contact dermatitis 29.8 TLR2 IL4 IL18 IL10 CD4
22 bronchopneumonia 29.8 PI3 IL10 CD8A CD4
23 immune deficiency disease 29.8 TLR2 IL4 IL18 IL10 CD80 CD4
24 anogenital venereal wart 29.7 TLR2 CD8A CD4 CCR6
25 exanthem 29.7 IL10 CD8A CD4 CCR6
26 chickenpox 29.7 TLR2 IL4 IL10 GYPC CD8A CD4
27 listeriosis 29.6 TLR2 TBX21 IL10 CD8A CD4 CCR6
28 herpes zoster 29.6 TLR2 IL10 GYPC CD8A CD4 CCR6
29 autoimmune disease 29.6 IL4 IL18 IL10 CD80 CCR6 CCL5
30 crohn's disease 29.5 TLR2 IL4 IL18 IL10 CD4 CCR6
31 human immunodeficiency virus infectious disease 29.4 IL4 IL10 CD8A CD80 CD4 CCR6
32 leukemia, chronic lymphocytic 29.3 IL4 IL10 CD8A CD80 CD4 CCR6
33 meningoencephalitis 29.3 IL4 IL10 CD8A CD4 CCR6 CCL5
34 herpetic whitlow 29.3 TNFRSF14 NECTIN1 GYPC CD4 ACKR1
35 peripheral nervous system disease 29.3 TLR2 IL4 IL10 CD8A CD4 CCR6
36 skin disease 29.2 TLR2 PI3 IL4 IL18 IL10 CD8A
37 eye disease 29.1 TLR2 IL4 IL10 CD8A CD4 CCR6
38 vaginitis 29.0 TLR2 IL10 CD4 CCR6 CCL5 ATAD2
39 diabetes mellitus 29.0 TLR2 IL4 IL18 IL10 CD80 CD4
40 bacterial infectious disease 28.7 TLR2 PI3 IL18 IL10 CD8A CD80
41 vaginal disease 28.6 TLR2 IL10 CD8A CD4 CCR6 CCL5
42 herpes simplex encephalitis 11.6
43 mollaret meningitis 11.4
44 congenital herpes simplex 11.3
45 neonatal herpes 10.7
46 tropical endomyocardial fibrosis 10.6 IL4 IL10
47 spotted fever rickettsiosis 10.5 IL10 CCL5
48 cutaneous leishmaniasis 10.5 TLR2 IL4 IL10
49 neurosyphilis 10.5 TLR2 IL10
50 orofacial granulomatosis 10.5 IL4 IL10 CCL5
51 periapical granuloma 10.5 TLR2 IL4 CCL5
52 autoimmune hepatitis type 1 10.4 IL4 IL10
53 acute graft versus host disease 10.4 IL4 IL18 IL10
54 penicillin allergy 10.4 IL4 IL18 IL10
55 blau syndrome 10.4 TLR2 IL4 IL10
56 paracoccidioidomycosis 10.4 TLR2 IL4 IL10
57 rheumatic heart disease 10.4 TLR2 IL4 IL10
58 aggressive periodontitis 10.4 TLR2 IL4 IL10
59 scrub typhus 10.4 TLR2 IL18 IL10
60 subacute sclerosing panencephalitis 10.4 IL4 IL18 IL10
61 allergic contact dermatitis 10.4 IL4 IL10 CD4
62 tonsillitis 10.4 TLR2 IL4 IL10
63 urinary schistosomiasis 10.4 IL4 IL10 CD80
64 milk allergy 10.4 IL4 IL18 IL10
65 chronic inflammatory demyelinating polyradiculoneuropathy 10.4 TBX21 IL10 CCL5
66 polyradiculoneuropathy 10.4 TBX21 IL10 CCL5
67 chronic graft versus host disease 10.4 IL10 CD4
68 trichinosis 10.4 IL4 IL10 CD4
69 silicosis 10.4 IL4 IL18 IL10
70 brucellosis 10.4 IL4 IL18 IL10
71 vulvovaginitis 10.4 IL10 CCR6 CCL5
72 vulvovaginal candidiasis 10.4 TLR2 IL4 CCR6
73 melioidosis 10.4 TLR2 IL18 IL10
74 dengue hemorrhagic fever 10.4 IL4 IL18 IL10
75 amebiasis 10.4 TLR2 IL4 CD4
76 necrotizing gastritis 10.4 GYPC ACKR1
77 esophagitis 10.4 IL4 IL10 CCL5
78 peanut allergy 10.4 IL4 IL10 CCR6
79 drug-induced lupus erythematosus 10.4 IL4 IL10 CD4
80 leishmaniasis 10.4 TLR2 IL4 IL18 IL10
81 chorioamnionitis 10.4 IL4 IL18 IL10
82 pulmonary eosinophilia 10.3 IL4 CCR6 CCL5
83 q fever 10.3 TLR2 IL4 IL10 CCL5
84 perinatal necrotizing enterocolitis 10.3 TLR2 IL10 CCR6
85 bacterial meningitis 10.3 TLR2 IL18 IL10
86 cork-handlers' disease 10.3 CD8A CD4
87 bronchiolitis 10.3 TLR2 IL4 IL10 CCL5
88 osteomyelitis 10.3 TLR2 IL4 IL10 CCL5
89 eye lymphoma 10.3 IL10 CD4
90 rosacea 10.3 TLR2 IL18 CCR6
91 mycoplasma pneumoniae pneumonia 10.3 TLR2 IL4 IL18 IL10
92 lepromatous leprosy 10.3 TLR2 IL4 IL18 IL10
93 cysticercosis 10.3 IL18 IL10 CD4
94 familial mediterranean fever 10.3 TLR2 IL18 IL10
95 leptospirosis 10.3 TLR2 IL4 IL18 IL10
96 aphthous stomatitis 10.3 TLR2 IL4 IL18 IL10
97 bronchitis 10.3 TLR2 IL4 IL10 CCL5
98 food allergy 10.3 TLR2 IL4 IL10
99 visceral leishmaniasis 10.3 TLR2 IL4 IL18 IL10
100 extrapulmonary tuberculosis 10.3 TLR2 IL10 CD4
101 pulmonary tuberculosis 10.3 TLR2 IL4 IL18 IL10
102 takayasu arteritis 10.3 IL18 IL10 CCL5
103 otitis media 10.3 TLR2 IL4 IL10 CCL5
104 periodontitis 10.3 TLR2 IL4 IL18 IL10
105 yellow fever 10.3 IL4 CCR6 CCL5
106 autoimmune vasculitis 10.3 IL4 CD4 CCR6
107 alcoholic hepatitis 10.3 TLR2 IL18 IL10
108 ventilation pneumonitis 10.3 CD8A CD4
109 schistosomiasis 10.3 IL4 IL10 CD80 CCL5
110 autoimmune polyendocrine syndrome 10.3 IL18 IL10 CCR6
111 diffuse infiltrative lymphocytosis syndrome 10.3 CD8A CD4
112 pulmonary sarcoidosis 10.3 IL18 CCR6 CCL5
113 plasmodium falciparum malaria 10.3 IL4 IL18 IL10
114 echinococcosis 10.3 TLR2 IL10 CD8A
115 igg4-related disease 10.3 IL4 CD4 CCR6
116 diabetes mellitus, insulin-dependent, 23 10.3 CD8A CD4
117 autoimmune lymphoproliferative syndrome, type iia 10.3 CD8A CD4
118 keratoconjunctivitis sicca 10.3 IL4 CD4 CCR6
119 secondary progressive multiple sclerosis 10.3 IL4 IL10 CCR6
120 early yaws 10.3 CD8A CD4
121 interstitial lung disease 10.3 IL4 IL18 IL10 CCL5
122 balanoposthitis 10.3 GYPC ACKR1
123 reactive arthritis 10.3 TLR2 IL10 CCR6
124 cervical cancer 10.3
125 immunodeficiency with hyper-igm, type 1 10.3 IL4 CD4 CCR6
126 filarial elephantiasis 10.3 TLR2 IL4 IL10 CD4
127 spondyloarthropathy 10.3 IL4 IL10 CCR6
128 central nervous system hematologic cancer 10.3 IL10 CD4 CCR6
129 vogt-koyanagi-harada disease 10.3 TLR2 IL10 CD8A
130 hyper ige syndrome 10.3 TLR2 IL4 IL10 CCR6
131 bird fancier's lung 10.3 CD8A CD4
132 chronic fatigue syndrome 10.2 IL4 IL10 CCL5
133 allergic rhinitis 10.2 IL4 IL18 IL10 CCL5
134 retinitis pigmentosa 46 10.2 IL4 CD8A CD4
135 bullous skin disease 10.2 CD4 CCR6 CCL5
136 superficial basal cell carcinoma 10.2 TLR2 CD8A CD4
137 combat disorder 10.2 TLR2 CD8A CD4
138 parapsoriasis 10.2 CD8A CD4
139 bacterial sepsis 10.2 TLR2 IL18 IL10 CCR6
140 norwegian scabies 10.2 CD8A CD4
141 mastitis 10.2 TLR2 IL18 CCR6 CCL5
142 chorioretinitis 10.2 IL10 CD8A CD4
143 macs syndrome 10.2 IL10 CD8A CD4
144 inclusion body myopathy with early-onset paget disease of bone with or without frontotemporal dementia 1 10.2 CD8A CD4 ACKR1
145 congenital toxoplasmosis 10.2 IL10 CD8A CD4
146 psoriatic arthritis 10.2 TLR2 IL4 IL10 CCR6
147 hashimoto thyroiditis 10.2 IL4 IL18 IL10 CD80
148 stachybotrys chartarum 10.2 IL18 CCL5
149 kawasaki disease 10.2 IL4 IL18 IL10 CD4
150 urethritis 10.2
151 cerebral palsy 10.2 IL4 IL18 IL10 APOE
152 thrombocytopenic purpura, autoimmune 10.2 IL18 CD4 CCR6
153 multidrug-resistant tuberculosis 10.2 IL10 CD8A CD4
154 penile disease 10.2 TLR2 CD8A CD4
155 farmer's lung 10.2 PI3 CD8A CD4
156 oral cavity cancer 10.2 TLR2 IL4 IL18 CCR6
157 primary progressive multiple sclerosis 10.2 IL4 IL10 CCR6 APOE
158 chlamydia pneumonia 10.2 TLR2 IL10 CD4 APOE
159 neurogenic bladder 10.2
160 skin sarcoidosis 10.2 CD8A CD4
161 gingivitis 10.2 TLR2 IL4 IL18 IL10 CCL5
162 proteasome-associated autoinflammatory syndrome 1 10.2 TLR2 IL4 IL18 IL10 CCL5
163 lymphopenia 10.2 IL4 IL18 IL10 CCR6
164 trypanosomiasis 10.2 TLR2 IL4 IL18 IL10 CCL5
165 mikulicz disease 10.2 IL4 IL10 CD4 CCR6
166 peritonitis 10.2 TLR2 IL4 IL18 IL10 CCL5
167 variola major 10.2 CD8A CD4
168 allergic asthma 10.2 TLR2 IL4 IL18 IL10 CCL5
169 egg allergy 10.2 IL4 IL10 CD4 CCR6
170 suppressor of tumorigenicity 3 10.2
171 chancroid 10.2
172 legume allergy 10.2 IL4 IL10 CD4 CCR6
173 fruit allergy 10.2 IL4 IL10 CD4 CCR6
174 chronic conjunctivitis 10.2 IL4 IL10 CD4 CCR6
175 folliculitis 10.2 IL4 CD4 CCR6 CCL5
176 intestinal schistosomiasis 10.2 IL4 IL10 CD4 CCR6
177 immunodeficiency with hyper-igm, type 3 10.2 CD8A CD80 CD4
178 autoimmune gastritis 10.2 IL4 IL10 CD4 CCR6
179 tuberculoid leprosy 10.2 TLR2 IL10 CD4 CCR6
180 mast cell neoplasm 10.2 CD8A CD80 CD4
181 gingival disease 10.2 TLR2 IL10 CD4 CCR6
182 esophageal candidiasis 10.2 CD8A CD4 CCR6
183 dysentery 10.2 TLR2 IL10 CD4 CCR6
184 invasive aspergillosis 10.2 TLR2 IL10 CD4 CCR6
185 iritis 10.1 CD8A CD4 CCR6
186 central nervous system vasculitis 10.1 CD8A CD4 CCR6
187 follicular mucinosis 10.1 CD8A CD4
188 laryngotracheitis 10.1 GYPC ACKR1
189 autoimmune glomerulonephritis 10.1 CD8A CD4 CCR6
190 autoimmune disease of urogenital tract 10.1 CD8A CD4 CCR6
191 toxic shock syndrome 10.1 TLR2 IL4 IL10
192 t-cell adult acute lymphocytic leukemia 10.1 CD8A CD4 CCR6
193 adult acute lymphocytic leukemia 10.1 CD8A CD4 CCR6
194 human immunodeficiency virus type 1 10.1
195 aseptic meningitis 10.1
196 neutropenia 10.1
197 cytokine deficiency 10.1
198 pneumocystosis 10.1 CD8A CD4 CCR6
199 viral exanthem 10.1 CD8A CD4
200 cowpox 10.1 CD8A CD80 CD4
201 histoplasmosis 10.1 CD8A CD4 CCR6
202 metal allergy 10.1 IL4 IL10 CD8A CD4
203 immunoglobulin alpha deficiency 10.1 CD8A CD4 CCR6
204 nickel allergic contact dermatitis 10.1 IL4 IL10 CD8A CD4
205 anemia, autoimmune hemolytic 10.1 CD8A CD4 CCR6
206 t cell deficiency 10.1 CD8A CD4 CCR6
207 plasma protein metabolism disease 10.1 CD8A CD4 CCR6
208 taeniasis 10.1 IL4 IL10 CD8A CD4
209 lymphadenitis 10.1 IL18 IL10 CD4 CCR6
210 tertiary syphilis 10.1 CD8A CD4
211 orchitis 10.1 IL4 IL10 CD8A CD4
212 arteriosclerosis 10.1 IL4 IL18 IL10 CCL5 APOE
213 nail disease 10.1 CD8A CD4 CCR6
214 pneumonic plague 10.1 TLR2 IL10 CD8A CD4
215 plague 10.1 TLR2 IL10 CD8A CD4
216 poliomyelitis 10.1 IL4 IL10 CD8A CD4
217 chagas disease 10.1 TLR2 IL4 IL10 CD4 CCL5
218 spongiotic dermatitis 10.1 CD8A CD4
219 progressive multifocal leukoencephalopathy 10.1 CD8A CD4 CCR6
220 coronavirus infectious disease 10.1 CD8A CD4 CCR6
221 thymus gland disease 10.1 CD8A CD4 CCR6
222 thymus cancer 10.1 CD8A CD4 CCR6
223 invasive malignant thymoma 10.1 CD8A CD4
224 erythema multiforme 10.1
225 myelitis 10.1
226 granuloma inguinale 10.1
227 colitis 10.1 TLR2 IL4 IL18 IL10 CCR6
228 lymphoma, mucosa-associated lymphoid type 10.1 TLR2 CD80 CD4 CCR6
229 granulomatosis with polyangiitis 10.1 TLR2 CD80 CD4 CCR6
230 epidermodysplasia verruciformis 1 10.1 CD8A CD4 CCR6
231 lassa fever 10.1 GYPC CD8A CD4
232 pleural disease 10.1 CD8A CD4 CCR6
233 balanitis 10.0
234 pemphigoid gestationis 10.0
235 hyperuricemia 10.0
236 secondary syphilis 10.0
237 rubella 10.0
238 cervix uteri carcinoma in situ 10.0
239 cervical intraepithelial neoplasia 10.0
240 meningitis and encephalitis 10.0
241 blepharitis 10.0 IL4 CD8A CD4 CCR6
242 vitiligo-associated multiple autoimmune disease susceptibility 1 10.0 CD8A CD4 CCR6
243 pneumonic tularemia 10.0 TLR2 CD8A CD4 CCR6
244 glucose metabolism disease 10.0 IL10 CD4 CCR6 APOE
245 fallopian tube disease 10.0 TLR2 CD8A CD4 CCR6
246 blepharoconjunctivitis 10.0 IL4 CD4
247 ileitis 10.0 TLR2 IL10 CD4 CCR6 CCL5
248 acquired metabolic disease 10.0 IL10 CD4 CCR6 APOE
249 diabetes mellitus, ketosis-prone 10.0
250 lymphogranuloma venereum 10.0
251 trichomoniasis 10.0
252 in situ carcinoma 10.0
253 molluscum contagiosum 10.0
254 eczema herpeticum 10.0
255 cytomegalovirus infection 10.0
256 primary thrombocytopenia 10.0 IL10 CD8A CD4 CCR6
257 thrombocytopenia due to platelet alloimmunization 10.0 IL10 CD8A CD4 CCR6
258 autoimmune disease of peripheral nervous system 10.0 IL10 CD8A CD4 CCR6
259 allergic hypersensitivity disease 10.0 IL4 IL10 CD4 CCR6 CCL5
260 mature b-cell neoplasm 10.0 CD8A CD4 CCR6
261 panuveitis 10.0 IL10 CD8A CD4 CCR6
262 temporal arteritis 10.0 CD8A CD4 CCR6 CCL5
263 spinal cord disease 10.0 IL10 CD8A CD4 CCR6
264 salivary gland disease 10.0 IL10 CD8A CD4 CCR6
265 stomach disease 10.0 IL10 CD8A CD4 CCR6
266 acute cystitis 10.0 TLR2 IL18 IL10 CD4 CCR6
267 blood coagulation disease 10.0 IL10 CD8A CD4 CCR6
268 cholangitis, primary sclerosing 10.0 IL10 CD8A CD4 CCR6
269 x-linked monogenic disease 10.0 IL10 CD8A CD4 CCR6
270 ectodermal dysplasia 1, hypohidrotic, x-linked 10.0 NECTIN1 IL10 CD8A CD4
271 aspergillosis 10.0 TLR2 IL4 IL18 IL10 CCR6 CCL5
272 ectodermal dysplasia 10b, hypohidrotic/hair/tooth type, autosomal recessive 10.0 NECTIN1 IL10 CD8A CD4
273 sialadenitis 10.0 CD8A CD80 CD4 CCR6
274 epidemic typhus 10.0 TLR2 IL10 CD8A CD4 CCL5
275 brachydactyly, type c 10.0 CD8A CD80 CD4 CCR6
276 lymphoid interstitial pneumonia 10.0 NECTIN1 CD8A CD4
277 thrombocytopenia 10.0 TLR2 TBX21 IL4 IL18 IL10 APOE
278 aplastic anemia 10.0 TBX21 IL4 IL18 IL10 CD4
279 cerebritis 10.0 CD8A CD4
280 blood platelet disease 9.9 CD8A CD4 CCR6
281 mucocutaneous leishmaniasis 9.9 IL4 IL10 CD8A CD4 APOE
282 cytomegalovirus retinitis 9.9 IL10 GYPC CD8A CD4
283 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.9
284 diarrhea 9.9
285 urticaria 9.9
286 cystitis 9.9
287 impotence 9.9
288 constipation 9.9
289 phimosis 9.9
290 primary syphilis 9.9
291 radiculopathy 9.9
292 nervous system disease 9.9
293 48,xyyy 9.9
294 postherpetic neuralgia 9.9
295 acute liver failure 9.9
296 thrombotic microangiopathy 9.9
297 relapsing-remitting multiple sclerosis 9.9 IL4 IL18 IL10 CCR6 CCL5 APOE
298 pneumonia 9.9 TLR2 IL4 IL18 IL10 CD8A CCL5
299 respiratory failure 9.9 IL10 CD4 CCR6 CCL5
300 intestinal disease 9.9 IL10 CD8A CD4 CCR6
301 dacryoadenitis 9.9 IL4 IL10 CD8A CD4 CCR6
302 fungal meningitis 9.9 IL4 IL10 CD8A CD4 CCR6
303 lichen disease 9.9 IL4 IL10 CD8A CD4 CCR6
304 common cold 9.9 TLR2 IL4 IL10 CD4 CCR6 CCL5
305 lacrimal apparatus disease 9.9 IL4 IL10 CD8A CD4 CCR6
306 cryptococcosis 9.9 IL4 IL10 CD8A CD4 CCR6
307 autoimmune disease of blood 9.9 IL4 IL10 CD8A CD4 CCR6
308 autoimmune disease of exocrine system 9.9 IL4 IL10 CD8A CD4 CCR6
309 autoimmune disease of skin and connective tissue 9.9 IL4 IL10 CD8A CD4 CCR6
310 paranasal sinus disease 9.9 IL4 IL10 CD8A CD4 CCR6
311 autoimmune disease of endocrine system 9.9 IL4 IL10 CD8A CD4 CCR6
312 b cell deficiency 9.9 IL4 IL10 CD8A CD4 CCR6
313 autoimmune disease of gastrointestinal tract 9.9 IL4 IL10 CD8A CD4 CCR6
314 hypotrichosis 1 9.9 IL4 IL10 CD8A CD4 CCR6
315 cellulitis 9.9 IL4 IL10 CD8A CD4 CCR6
316 uveal disease 9.9 IL4 IL10 CD8A CD4 CCR6
317 streptococcus pneumonia 9.9 TLR2 IL10 CD8A CD4 CCR6
318 hair disease 9.9 IL4 IL10 CD8A CD4 CCR6
319 middle ear disease 9.9 TLR2 IL10 CD8A CD4 CCR6
320 chediak-higashi syndrome 9.9 IL4 IL10 CD8A CD4 CCR6
321 anus disease 9.9 TLR2 IL10 CD8A CD4 CCR6
322 potocki-shaffer syndrome 9.9 IL4 IL10 CD8A CD4 CCR6
323 rectal disease 9.9 TLR2 IL10 CD8A CD4 CCR6
324 viral pneumonia 9.9 IL10 CD8A CD4 CCR6 CCL5
325 x-linked recessive disease 9.9 IL4 IL10 CD8A CD4 CCR6
326 sezary's disease 9.9 IL4 IL10 CD8A CD4 CCR6
327 leukocyte disease 9.9 IL4 IL10 CD8A CD4 CCR6
328 viral encephalitis 9.9 IL10 CD8A CD4 CCR6 CCL5
329 bacterial pneumonia 9.9 TLR2 IL10 CD8A CD4 CCR6
330 omenn syndrome 9.9 IL4 IL10 CD8A CD4 CCR6
331 tularemia 9.9 TLR2 IL18 CD8A CD4 CCR6
332 corneal disease 9.9 TLR2 IL10 CD8A CD4 CCR6
333 systemic scleroderma 9.9 IL4 IL10 CD8A CD4 CCR6
334 extrinsic allergic alveolitis 9.9 PI3 IL18 IL10 CD80 CCR6 CCL5
335 immune system disease 9.9 IL4 IL10 CD8A CD4 CCR6
336 inclusion body myopathy with paget disease of bone and frontotemporal dementia 9.8 IL10 GYPC CD8A CD4 ACKR1
337 connective tissue disease 9.8 IL4 IL10 CD8A CD4 CCR6
338 annular erythema 9.8
339 lichen sclerosus et atrophicus 9.8
340 benign chronic pemphigus 9.8
341 preterm premature rupture of the membranes 9.8
342 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.8
343 sexual disorder 9.8
344 cutaneous t cell lymphoma 9.8
345 physical disorder 9.8
346 pelvic inflammatory disease 9.8
347 viral meningitis 9.8
348 nasopharyngitis 9.8
349 hypospadias 9.8
350 cauda equina syndrome 9.8
351 optic neuritis 9.8
352 common variable immunodeficiency 9.8
353 varicocele 9.8
354 vulva cancer 9.8
355 hepatitis a 9.8
356 acute leukemia 9.8
357 squamous cell papilloma 9.8
358 squamous cell carcinoma 9.8
359 vulva squamous cell carcinoma 9.8
360 pharyngitis 9.8
361 papilloma 9.8
362 cervix carcinoma 9.8
363 anuria 9.8
364 proctitis 9.8
365 vaccinia 9.8
366 central nervous system disease 9.8
367 verrucous carcinoma 9.8
368 vaginal discharge 9.8
369 vulvitis 9.8
370 polyradiculopathy 9.8
371 elephantiasis 9.8
372 infertility 9.8
373 severe combined immunodeficiency 9.8
374 intestinal obstruction 9.8
375 actinomycosis 9.8
376 neuromyelitis optica 9.8
377 keratoconjunctivitis 9.8
378 congenital syphilis 9.8
379 hypereosinophilic syndrome 9.8
380 herpes virus antenatal infection 9.8
381 splenomegaly 9.8
382 autonomic dysfunction 9.8
383 back pain 9.8
384 chronic pain 9.8
385 headache 9.8
386 gastric adenocarcinoma and proximal polyposis of the stomach 9.8
387 transient pseudohypoaldosteronism 9.8
388 primary systemic mycosis 9.8 TLR2 IL4 IL10 CD8A CD4 CCR6
389 herpangina 9.8 TLR2 IL4 IL10 CD8A CD4 CCR6
390 splenic disease 9.8 TLR2 IL4 IL10 CD8A CD4 CCR6
391 coccidiosis 9.8 TLR2 IL4 IL10 CD8A CD4 CCR6
392 opportunistic mycosis 9.8 TLR2 IL4 IL10 CD8A CD4 CCR6
393 fungal infectious disease 9.8 TLR2 IL4 IL10 CD8A CD4 CCR6
394 lymph node disease 9.8 TLR2 IL4 IL10 CD8A CD4 CCR6
395 commensal bacterial infectious disease 9.8 TLR2 IL4 IL10 CD8A CD4 CCR6
396 extrinsic cardiomyopathy 9.8 TLR2 IL4 IL10 CD8A CD4 CCR6
397 testicular disease 9.8 TLR2 IL4 IL10 CD8A CD4 CCR6
398 leprosy 3 9.8 TLR2 IL4 IL10 CD8A CD4 CCR6
399 upper respiratory tract disease 9.8 TLR2 IL4 IL10 CD8A CD4 CCR6
400 demyelinating disease 9.7 IL4 IL10 CD8A CD4 CCR6 CCL5
401 arthritis 9.7 TLR2 IL4 IL18 IL10 CD80 CCR6
402 lung disease 9.7 TLR2 PI3 IL4 IL18 IL10 CD8A
403 salmonellosis 9.7 TLR2 IL18 IL10 CD8A CD4 CCR6
404 autoimmune disease of eyes, ear, nose and throat 9.7 TBX21 IL4 IL10 CD8A CD4 CCR6
405 granulomatous hepatitis 9.7 CD8A CD4
406 combined t cell and b cell immunodeficiency 9.7 IL4 IL10 CD8A CD80 CD4 CCR6
407 sarcoidosis 1 9.7 IL18 CD8A CD80 CD4 CCR6 CCL5
408 lymphoma, non-hodgkin, familial 9.7 IL4 IL10 CD8A CD80 CD4 CCR6
409 parasitic protozoa infectious disease 9.6 TLR2 IL4 IL10 CD8A CD4 CCR6
410 conjunctival disease 9.6 TLR2 IL4 IL10 CD8A CD4 CCR6
411 nasal cavity disease 9.6 TLR2 IL4 IL10 CD8A CD4 CCR6
412 nose disease 9.6 TLR2 IL4 IL10 CD8A CD4 CCR6
413 hypersensitivity reaction type iv disease 9.6 TLR2 IL4 IL18 IL10 CD8A CD4
414 viral infectious disease 9.6 TLR2 IL4 IL18 IL10 CD4 CCR6
415 chronic mucocutaneous candidiasis 9.6 TLR2 IL4 IL18 IL10 CD8A CD4
416 integumentary system disease 9.6 TLR2 IL4 IL18 IL10 CD8A CD4
417 mycobacterium tuberculosis 1 9.6 TLR2 IL4 IL18 IL10 CD8A CD4
418 leukemia, acute myeloid 9.6 IL4 IL10 CD8A CD80 CD4 CCR6
419 parasitic helminthiasis infectious disease 9.6 TLR2 TBX21 IL4 IL10 CD8A CD4
420 respiratory allergy 9.6 TBX21 IL4 IL10 CD8A CD4 CCR6
421 autoimmune disease of musculoskeletal system 9.6 TLR2 IL4 IL10 CD8A CD80 CD4
422 psoriasis 9.5 TLR2 PI3 IL4 IL18 IL10 CD4
423 myeloma, multiple 9.5 IL4 IL10 CD8A CD80 CD4 CCR6
424 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 9.5 TBX21 IL4 IL10 CD8A CD80 CD4
425 body mass index quantitative trait locus 11 9.5 TLR2 IL4 IL18 IL10 CD4 CCR6
426 rheumatoid arthritis 9.5 TLR2 IL4 IL18 IL10 CD80 CD4
427 acute retinal necrosis syndrome 9.5 TNFRSF14 NECTIN1 GYPC CD8A CD4
428 pulmonary fibrosis, idiopathic 9.5 TLR2 IL4 IL18 IL10 CD8A CD4
429 dermatitis, atopic 9.5 TLR2 IL4 IL18 IL10 CD8A CD4
430 bronchial disease 9.4 TLR2 TBX21 IL4 IL10 CD8A CD4
431 hypertension, essential 9.4 TLR2 IL4 IL18 IL10 CD8A CD4
432 bone inflammation disease 9.4 TLR2 IL4 IL18 IL10 CD8A CD80
433 behcet syndrome 9.4 TLR2 IL4 IL18 IL10 CD8A CD80
434 diabetes mellitus, type i 9.4 TLR2 IL4 IL18 IL10 CD8A CD80
435 cone-rod dystrophy 2 9.4 TNFRSF14 NECTIN1 CD8A CD80 CD4 ACKR1
436 diabetes mellitus, noninsulin-dependent 9.4 TLR2 IL4 IL18 IL10 CD8A CD4
437 asthma 9.3 TLR2 TBX21 IL4 IL18 IL10 CD80
438 inflammatory bowel disease 9.3 TLR2 TBX21 IL4 IL18 IL10 CD8A
439 primary bacterial infectious disease 9.3 IL18 IL10 CD8A CD80 CD4 CCR6
440 pulmonary disease, chronic obstructive 9.3 TLR2 PI3 IL4 IL10 CD8A CD80
441 autoimmune disease of central nervous system 9.2 TLR2 TBX21 IL4 IL10 CD8A CD80
442 celiac disease 1 9.2 TLR2 TBX21 IL4 IL18 IL10 CD8A
443 multiple sclerosis 9.1 TLR2 IL4 IL18 IL10 CD8A CD80
444 systemic lupus erythematosus 8.9 TLR2 TBX21 IL4 IL18 IL10 IFI16
445 malaria 8.8 TLR2 IL4 IL18 IL10 GYPC CD8A

Comorbidity relations with Genital Herpes via Phenotypic Disease Network (PDN): (showing 1, show less)


Acute Cystitis

Graphical network of the top 20 diseases related to Genital Herpes:



Diseases related to Genital Herpes

Symptoms & Phenotypes for Genital Herpes

Symptoms:

12 (showing 3, show less)
  • fever
  • sores
  • swollen glands

UMLS symptoms related to Genital Herpes:


fever, pruritus, pelvic pain

MGI Mouse Phenotypes related to Genital Herpes:

45 (showing 6, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.17 APOE CCL5 CCR6 CD4 CD80 CD8A
2 homeostasis/metabolism MP:0005376 10.07 ACKR1 APOE CCR6 CD4 GYPC IFI16
3 immune system MP:0005387 10.03 ACKR1 APOE CCL5 CCR6 CD4 CD80
4 digestive/alimentary MP:0005381 9.97 APOE CD4 IL10 IL18 IL4 TBX21
5 integument MP:0010771 9.61 APOE CD4 CD8A IFNE IL10 IL18
6 nervous system MP:0003631 9.36 APOE CCR6 CD4 CD80 CD8A IFI16

Drugs & Therapeutics for Genital Herpes

Drugs for Genital Herpes (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 35, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Famciclovir Approved, Investigational Phase 4 104227-87-4 3324
2
Metronidazole Approved Phase 4 443-48-1 4173
3
Acyclovir Approved Phase 4 59277-89-3 2022
4
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
5
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
6 Anti-HIV Agents Phase 4
7 Reverse Transcriptase Inhibitors Phase 4
8 Denatonium Phase 4
9 Anti-Infective Agents Phase 4
10 Antioxidants Phase 4
11 Protective Agents Phase 4
12 Anti-Bacterial Agents Phase 4
13 Antibiotics, Antitubercular Phase 4
14 Antiparasitic Agents Phase 4
15 Antiprotozoal Agents Phase 4
16
Halofantrine Approved Phase 3 69756-53-2 37393
17
Aluminum sulfate Approved Phase 3 10043-01-3
18 Vaccines Phase 3
19 Immunologic Factors Phase 3
20 polysaccharide-K Phase 3
21 Adjuvants, Immunologic Phase 3
22 interferons Phase 3
23 Monophosphoryl lipid A Phase 3
24 Radiation-Protective Agents Phase 3
25 Pritelivir Investigational Phase 2 348086-71-5
26 valacyclovir Phase 2
27 Antiviral Agents Phase 2
28 Immunoglobulins Phase 2
29 Antibodies Phase 2
30 Antibodies, Monoclonal Phase 2
31 Lecithin Phase 2
32
Glutamic acid Approved, Nutraceutical Phase 1 56-86-0 33032
33 Pharmaceutical Solutions Phase 1
34
Histidine Investigational, Nutraceutical Phase 1 71-00-1 6274
35 Anti-Retroviral Agents

Interventional clinical trials:

(showing 93, show less)
# Name Status NCT ID Phase Drugs
1 A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding Completed NCT00129818 Phase 4 Famciclovir
2 An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients Completed NCT00158860 Phase 4 Valaciclovir;Placebo
3 A Randomized, Multicenter, Double-blind Study to Compare the Efficacy of Single-day Treatment (1000 mg b.i.d.) With Famciclovir Compared to That of Placebo in Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Immunocompetent Black Patients Completed NCT00477334 Phase 4 Famciclovir;Placebo
4 A Study to Determine the Safety and Efficacy of Famciclovir in the Episodic and Suppressive Treatment of Recurrent Genital Herpes (RGH). The Study Will Also Evaluate Quality of Life and Patient Satisfaction Completed NCT00219310 Phase 4 Famciclovir
5 Effect of Tenofovir on Genital HSV Shedding: a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT01448616 Phase 4 TDF;Placebo Vaginal Gel;Vaginal TFV Gel;Placebo Tablets
6 A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of Acyclovir on Rapidly Cleared Herpes Simplex Virus Type 2 Genital Reactivation Episodes in Herpes Simplex Virus-2 Seropositive Adults Completed NCT00723229 Phase 4 acyclovir
7 A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of High-Dose Acyclovir Versus Once Daily Valacyclovir on Herpes Simplex Virus Type 2 Genital Shedding in Herpes Simplex Virus-2 Seropositive Adults Completed NCT00362297 Phase 4 acyclovir;valacyclovir
8 A Randomized, Open-label, Crossover Trial of the Effect of Dosing of Daily HSV-2 Suppressive Therapy on HSV Reactivation and Plasma HIV-1 Levels Among HIV-1/ HSV-2 Co-infected Persons Completed NCT00527618 Phase 4 valacyclovir;acyclovir
9 A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of High-Dose Valacyclovir Versus Once Daily Valacyclovir on Herpes Simplex Virus Type 2 Genital Shedding in Herpes Simplex Virus-2 Seropositive Adults Completed NCT01346475 Phase 4 valacyclovir;Valacyclovir
10 The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection Completed NCT00306293 Phase 4 valacyclovir
11 Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH Completed NCT00116844 Phase 4 Valaciclovir;Placebo
12 Effects of Melatonin in the Treatment of Genital Herpes Recruiting NCT03831165 Phase 4 Acyclovir 400 MG
13 Controlled, Multicenter, Randomized Parallel Group Pilot Study With 2 Treatment Arms in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis (BV) Recruiting NCT02042287 Phase 4 Metronidazole
14 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy of 2LHERP® in Patients With Recurrent Genital Herpes Infections Not yet recruiting NCT04235322 Phase 4 2LHERP®;Placebo
15 An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons With CD4+ Lymphocyte Count <100 Cells/mm3. Terminated NCT00079911 Phase 4 valacyclovir hydrochloride
16 Effect of Suppressive Therapy on Behavioral Determinants of HSV-2 Transmission Terminated NCT00495716 Phase 4 acyclovir;acyclovir
17 An International, Randomized, Double-Blind, Placebo-Controlled Study of Valacyclovir for the Suppression of Recurrent Ano-Genital HSV Infections in HIV-Infected Subjects Unknown status NCT00005663 Phase 3 Valacyclovir hydrochloride
18 Trial of Male Circumcision: HIV, STD and Behavioral Effects in Men, Women and the Community Unknown status NCT00124878 Phase 3
19 Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes Completed NCT00171990 Phase 3 Famciclovir
20 A Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Patient-initiated Famciclovir 1000 mg b.i.d. x 1 Day to Valacyclovir 500 mg b.i.d. x 3 Days in Immunocompetent Adults With Recurrent Genital Herpes Completed NCT00306787 Phase 3 Famciclovir;Valacyclovir;Placebo matching famciclovir;Placebo matching valacyclovir
21 A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Famciclovir 125 mg Comparing to Aciclovir 200 mg in Patients With Active Recurrent Genital Herpes Completed NCT01281007 Phase 3 Famciclovir;Aciclovir
22 Safety of SmithKline Beecham Biologicals' Herpes Simplex Candidate Vaccine (gD2t) With MPL & Its Efficacy to Prevent Genital Herpes Disease in HSV Positive or Negative Consorts of Subjects With Genital Herpes Disease Completed NCT00699764 Phase 3
23 A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir for the Reduction of HIV Acquisition Among High-Risk HSV-2 Seropositive, HIV Seronegative Individuals Completed NCT00076232 Phase 3 Acyclovir;Acyclovir placebo
24 Phase III Randomized Placebo-Controlled Trial of HSV-2 Suppression to Prevent HIV Transmission Among HIV-Discordant Couples Completed NCT00194519 Phase 3 Generic acyclovir;Placebo
25 An International Multi-centre, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of 0.5% and 2% PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection Completed NCT00262106 Phase 3 PRO 2000/5;Placebo
26 Study to Evaluate the Safety of GSK Biologicals' Herpes Simplex Candidate Vaccine (gD2t) With MPL in HSV Seropositive or Seronegative Subjects Without Genital Herpes Disease Completed NCT00698568 Phase 3
27 Open-label Study of ASP2151 in Herpes Simplex Patients Completed NCT02209324 Phase 3 ASP2151
28 A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of gD-Alum/MPL Vaccine in the Prevention of Genital Herpes Disease in Young Women Who Are HSV-1 and -2 Seronegative Completed NCT00057330 Phase 3
29 A Randomized, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention of Herpes Simplex Virus Transmission in Heterosexual Couples Completed NCT00001649 Phase 3 Valaciclovir
30 VALacyclovir In Delaying Antiretroviral Treatment Entry Completed NCT00860977 Phase 3 valacyclovir;Placebo
31 Phase III Study of ASP2151 in Herpes Simplex Patients ― A Double-blind, Placebo-controlled Study ― Completed NCT01959295 Phase 3 ASP2151;ASP2151 placebo
32 Impact of Episodic Acyclovir Therapy on Ulcer Duration and HIV Shedding From Genital Ulcers Among Men in South Africa Completed NCT00164424 Phase 2, Phase 3 Acyclovir
33 Effect of Safe Male Circumcision on Incidence of Infection by HIV, HSV-2 and of Genital Ulceration Terminated NCT00122525 Phase 3
34 A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 Therapeutic DNA Vaccines in Symptomatic HSV-2-Seropositive Adults Completed NCT02030301 Phase 1, Phase 2
35 A Randomized, Double-Blind Study to Evaluate a New Formulation of GEN-003 in Subjects With Genital HSV-2 Infection Completed NCT02515175 Phase 2 Placebo
36 A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes Completed NCT00486200 Phase 2 ASP2151;valacyclovir;Placebo
37 Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 - Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2 Completed NCT02300142 Phase 2
38 A Phase I/IIa, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study of the Safety and Immunogenicity of a HSV-2 Vaccine Containing Matrix M-2 Adjuvant in Individuals With Documented Genital HSV-2 Genital Infection Completed NCT01667341 Phase 1, Phase 2
39 A Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Varying Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2 Infection Completed NCT02114060 Phase 2
40 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection Completed NCT02837575 Phase 2
41 Assessment of Local Retention and Duration of Activity of SPL7013 Following Vaginal Application of 3% SPL7013 Gel (VivaGel) in Healthy Volunteers Completed NCT00740584 Phase 1, Phase 2 3% SPL7013 Gel (VivaGel)
42 Efficacy of an HSV2 Genital Herpes Suppressive Treatment on HIV and HSV2 Genital Shedding Among Co-Infected Patients Receiving or Not Antiretroviral Drugs Completed NCT00158509 Phase 2 Valacyclovir
43 A Phase 2a Multicenter, Double-blinded, Randomized Trial to Evaluate The Effect of HerpV on Viral Shedding in Adults With Recurrent Genital Herpes Completed NCT01687595 Phase 2 HerpV and QS-21;Placebo
44 Anti-Herpetic Treatment Associated With Syndromic Management of Genital Ulcer in Africa: Clinical and Biological Evaluation on HIV-1 and HSV-2 Shedding (ANRS 1212) Completed NCT00158483 Phase 2 Acyclovir (ACV)
45 A Double-blind Randomized Placebo Controlled Dose-finding Trial to Investigate Different Doses of a New Antiviral Drug in Subjects With Genital HSV Type 2 Infection Completed NCT01047540 Phase 2 AIC316;AIC316;AIC316;AIC316;Placebo
46 A Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir Prophylaxis Versus Placebo Among HIV-1/HSV-2 Co-Infected Individuals in Uganda Completed NCT00405821 Phase 2 Acyclovir;Placebo
47 HSV-1 Suppression in HCV Infected Veterans Who Are Seronegative for HSV-2 Completed NCT01580995 Phase 2 Valacyclovir;Placebo
48 A Phase II, Randomized, Double-blind, Placebo-controlled Trial of Acyclovir for the Suppression of Human Immunodeficiency Virus Type 1 (HIV-1) Viral Load and Mucosal Shedding in HIV-1, Herpes Simplex Virus, Type 2 (HSV-2) Co-Infected Women Completed NCT00371592 Phase 2 Acyclovir;Acyclovir placebo
49 Safety and Efficacy of 4 Investigational HSV 2 Vaccines Administered by Intramuscular Route in Adults With Recurrent Genital Herpes Caused by HSV 2 Recruiting NCT04222985 Phase 1, Phase 2
50 A Randomized, Double-Blind, Double-Dummy Phase II Study of Single Dose HDIT101 Versus Standard of Care Valaciclovir in Patients With Chronic Recurrent Anogenital HSV-2 Infection Recruiting NCT04165122 Phase 2 Valaciclovir;Valaciclovir placebo
51 Anti-viral Therapy in Alzheimer's Disease Recruiting NCT03282916 Phase 2 Valacyclovir;Placebo
52 A Two-Stage, Randomized, Double-Blind, Dose-Ranging, Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621 on HSV Shedding in Adults With Recurrent Genital HSV-2 Infection. Not yet recruiting NCT03595995 Phase 2
53 A Phase II Open-label, Intra-individual Controlled, Single-center Study to Investigate the Efficacy, Safety and Tolerability of a Polyethylene Glycol-formulation and the Viral Shedding in Patients Suffering From Genital Herpes Terminated NCT01765114 Phase 2 PEG-Formulation
54 A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection Terminated NCT03146403 Phase 2
55 A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of "AIC316 (Pritelivir)" 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults. Terminated NCT01658826 Phase 2 AIC316;Valacyclovir
56 Human OK99 Allogeneic Stem Cell Transplantation for Patients With Severe Parkinson's Disease Unknown status NCT02780895 Phase 1 Human Stem Cells
57 A Phase 1 Trial Evaluating Safety, Tolerability and Immune Response of AG-707 Compared to Placebo in HSV-2 Seropositive Patients Completed NCT00231049 Phase 1 AG-707
58 A Phase I, Two-Center, Open-Label, Dose-Escalating Study to Investigate the Safety, Tolerability and Immunogenicity of pPJV7630, a Therapeutic DNA Vaccine for Herpes Simplex Virus Type 2 (HSV-2), in Patients With Recurrent Genital Herpes Caused by HSV-2 Completed NCT00274300 Phase 1
59 A Double-Blind, Placebo-Controlled Single Dose Escalating Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2151 in Healthy Male Subjects, Followed by an Open, Two-Period Crossover Study to Assess the Effect of Fed Conditions on the Safety, Tolerability and Pharmacokinetics of ASP2151 Completed NCT02852876 Phase 1 ASP2151;Placebo
60 Phase I Study of the Safety of Replication-Defective Herpes Simplex Virus-2 Vaccine, HSV529, in Adults Aged 18 to 40 Years With or Without HSV Infection Completed NCT01915212 Phase 1
61 Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and Herpes Simplex Virus 2 (HSV-2) Infection (Phase I) Completed NCT01453075 Phase 1 Valacyclovir;Placebo
62 An Expanded Phase I Randomized Placebo Controlled Trial of the Safety and Tolerability of 3 Percent w/w SPL7013 Gel (VivaGel™) in Healthy Young Women When Administered Twice Daily for 14 Days Completed NCT00331032 Phase 1 3% w/w SPL7013 Gel;Placebo
63 Safety, Efficacy, and Patient Satisfaction of Cervical Ripening With Transcervical Use of the Foley Catheter in an Outpatient Setting Unknown status NCT01605474
64 A Single Center, Open Label, Longitudinal Single Arm Study to Compare the Efficacy and Safety of Prophylactic Famciclovir 500 mg b.d. in HIV Positive Adults With Recurrent Genital Herpes. Completed NCT01154543
65 A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection Completed NCT02910284
66 Prospective Study of Pharmacokinetics, Clinical and Virologic Response to Acyclovir Episodic Therapy for Genital Herpes Ulcers in HIV Negative African Women Completed NCT02053142 Acyclovir;Placebo
67 Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis) Completed NCT01390805 Valaciclovir Hydrochloride.
68 The Effect of Treatment With Valacyclovir 500 mg BID on the Detection of HIV From Genital HSV Lesions in HIV-Infected Patients: A Double-Blind Crossover Study Completed NCT00002404 Valacyclovir hydrochloride
69 Prospective Study of Pharmacokinetics, Clinical and Virologic Response to Acyclovir Episodic Therapy for Genital Herpes Ulcers in HIV Negative African Women Completed NCT00808405 acyclovir;matching placebo
70 Half-life and Pattern of Resolution of Herpes Simplex Virus Type 2 (HSV-2) Shedding After Beginning Acyclovir Treatment Completed NCT00495573 acyclovir
71 The VIBLOK SAfety and perFormancE Trial Completed NCT03080961
72 Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2: Development of Testing Strategies Completed NCT01112956
73 HIV Prevalence, Incidence and HSV-2 Prevalence Among High-Risk MSM in Lima, Peru Completed NCT00023582
74 Persistence of Epstein-Barr Virus in Vivo Completed NCT00005924
75 A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Valacyclovir Caplets Under Fasting Conditions Completed NCT01132729 Valacyclovir Hydrochloride
76 A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Valacyclovir Caplets Under Fed Conditions Completed NCT01132716 Valacyclovir Hydrochloride
77 HSV Seroprevalence and Diagnosis of Genital Herpes in Pregnant Women Completed NCT00291044
78 A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients Completed NCT00002084 Valacyclovir hydrochloride;Acyclovir
79 A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients Completed NCT00002000 Valacyclovir hydrochloride;Acyclovir
80 Sexually Transmitted Infections Among African American Women Who Have Sex With Women Completed NCT01546714
81 Examining the Ability of HSV2 Therapy to Reduce HIV Target Cell Numbers in the Cervix. Completed NCT00946556 Valacyclovir;Placebo
82 DNA Clearance of Uncomplicated Trichomonas Vaginalis Infections in HIV Negative Women Completed NCT01874158
83 Seroprevalence of HSV-2 in HIV Infected Subjects and the Effect of Daiy Valacyclovir in the Reduction of HSV-2 Recurrences and Viral Shedding Completed NCT00803543 Valacyclovir;Placebo
84 Polymorphism of the Herpes Simplex Virus Receptor Completed NCT00001648
85 A Case Control Study of Women With Multiple Sexual Partners Attending the Jefferson County Department of Health Sexually Transmitted Diseases Clinic Completed NCT01578915
86 Impact Evaluation of a School-Based Sexuality and HIV Prevention Education Activity in South Africa Completed NCT04205721
87 A Randomized Controlled Trial Evaluating Efficacy of Promoting Voluntary Medical Male Circumcision Among Male Sexually Transmitted Diseases Patients in China Completed NCT03414710
88 Comparative Effectiveness of Treatment Options for Genital Herpes Infection in Pregnant Women to Reduce Adverse Pregnancy Outcomes Active, not recruiting NCT02986802
89 Safety and Efficacy of Er:YAG and Nd:YAG Laser Therapy in Gynecology: A Retrospective Case Series. Active, not recruiting NCT04073082
90 Herpesviruses Reactivation In Hiv-Infected Women Initiating ART (HERA) Active, not recruiting NCT03092505
91 NOWDx Test for the Diagnosis of Herpes Simplex Virus Type 2 Not yet recruiting NCT04294030
92 Evaluation of Different Methods for Rapid Diagnosis of Meningitis in Assiut University Hospital Not yet recruiting NCT03759470
93 An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative Persons Withdrawn NCT01059084 Valacyclovir

Search NIH Clinical Center for Genital Herpes

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Acyclovir
Acyclovir Sodium
famciclovir
Foscarnet
Foscarnet Sodium Hexahydrate
Interferon Alfa-2b
valacyclovir
Valacyclovir hydrochloride

Cochrane evidence based reviews: herpes genitalis

Genetic Tests for Genital Herpes

Anatomical Context for Genital Herpes

The Foundational Model of Anatomy Ontology organs/tissues related to Genital Herpes:

19
Genital System, Rectum

MalaCards organs/tissues related to Genital Herpes:

40
Testes, T Cells, Skin, Lymph Node, Cervix, Liver, Nk Cells

Publications for Genital Herpes

Articles related to Genital Herpes:

(showing 3252, show less)
# Title Authors PMID Year
1
Drug-encapsulated carbon (DECON): A novel platform for enhanced drug delivery. 42 61
31453334 2019
2
Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial. 61 42
31846475 2019
3
Herpes Simplex Virus Type 2 Seroprevalence in Pregnant Women in Urmia, Northwest of Iran, during 2014-2015 42
31677608 2020
4
Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. 61 54
19702506 2009
5
Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. 61 54
7911177 1994
6
Passive immunization of the vagina protects mice against vaginal transmission of genital herpes infections. 54 61
8158042 1994
7
Unilateral inguinal lymphadenitis caused by Yersinia pseudotuberculosis. A case report. 61
32386928 2020
8
Impact of a single-age cohort human papillomavirus vaccination strategy in Catalonia, Spain: Population-based analysis of anogenital warts in men and women. 61
32565118 2020
9
Viral ribonucleotide reductase attenuates the anti-herpes activity of acyclovir in contrast to amenamevir. 61
32569704 2020
10
Genital herpes and pregnancy: Evaluating practices and knowledge of French health care providers. 61
32122691 2020
11
Vaccines to prevent genital herpes. 61
32272093 2020
12
Hypertrophic genital herpes in an HIV-infected female patient: Imiquimod as an alternative treatment. 61
32311452 2020
13
Characteristics of genital herpes in Bilbao (Northern Spain): 12-year retrospective study. 61
32563583 2020
14
Use of the guinea pig model of genital herpes to evaluate vaccines and antivirals: review. 61
32544409 2020
15
The Chinese herbal prescription JZ-1 induces autophagy to protect against herpes simplex Virus-2 in human vaginal epithelial cells by inhibiting the PI3K/Akt/mTOR pathway. 61
32088246 2020
16
Association of HIV-syphilis coinfection with optimal antiretroviral adherence: a nation-wide claims study. 61
31690082 2020
17
Valacyclovir-Induced Thrombotic Thrombocytopenic Purpura. 61
32550073 2020
18
Self-Reported Prevalence of HIV Testing Among Those Reporting Having Been Diagnosed With Selected STIs or HCV, United States, 2005-2016. 61
32332427 2020
19
Carrageenan-Based Acyclovir Mucoadhesive Vaginal Tablets for Prevention of Genital Herpes. 61
32403219 2020
20
Management of Genital Herpes in Pregnancy: ACOG Practice Bulletin Summary, Number 220. 61
32332408 2020
21
Management of Genital Herpes in Pregnancy: ACOG Practice Bulletinacog Practice Bulletin, Number 220. 61
32332414 2020
22
Multivalent DNA vaccine protects against genital herpes by T-cell immune induction in vaginal mucosa. 61
32112797 2020
23
[Anal herpes simplex virus infections]. 61
31965208 2020
24
Prevention and treatment of neonatal herpes simplex virus infection. 61
32044154 2020
25
Cutting Edge: The Use of Topical Aminoglycosides as an Effective Pull in "Prime and Pull" Vaccine Strategy. 61
32122994 2020
26
Herpes simplex virus type 2 trivalent protein vaccine containing glycoproteins C, D and E protects guinea pigs against HSV-1 genital infection. 61
32347775 2020
27
Neonatal Herpes Simplex Virus: The Long Road to Improved Outcomes. 61
32317339 2020
28
Genital Ulcers: Differential Diagnosis and Management. 61
32163252 2020
29
Antiviral effect of Chinese herbal prescription JieZe-1 on adhesion and penetration of VK2/E6E7 with herpes simplex viruses type 2. 61
31743766 2020
30
An unusual presentation of genital herpes in a patient affected by lichen sclerosus et atrophicus: A case report and a combined treatment proposal. 61
31997518 2020
31
Donovanosis and genital herpes coinfection in a woman with human immunodeficiency virus infection: A case letter. 61
32258347 2020
32
Update: Sexually transmitted infections, active component, U.S. Armed Forces, 2011-2019. 61
32228001 2020
33
Effects of CD4 cell count and antiretroviral therapy on mucocutaneous manifestations among HIV/AIDS patients in Yunnan, China. 61
31846069 2020
34
T cell response kinetics determines neuroinfection outcomes during murine HSV infection. 61
32161194 2020
35
Self-Reported Prevalence of HIV Testing Among Those Reporting Having Been Diagnosed with Selected Sexually Transmitted Infections or Hepatitis C, United States, 2005-2016. 61
32044861 2020
36
Peculiar vegetative tumor-like genital herpes simplex nodules with brisk tissue eosinophilia in patients with human immunodeficiency virus infection. 61
31437312 2020
37
Genital zoster in near term pregnancy: Case report and need of management guidelines. 61
31852623 2020
38
Genital herpes zoster in an immunocompetent child. 61
32031528 2020
39
Antiviral therapy: Valacyclovir Treatment of Alzheimer's Disease (VALAD) Trial: protocol for a randomised, double-blind,placebo-controlled, treatment trial. 61
32034019 2020
40
Herpes Simplex Infection During Pregnancy, Results of a Tertiary Referral Center in Turkey. 61
30831604 2020
41
Vaccines for Herpes Simplex: Recent Progress Driven by Viral and Adjuvant Immunology. 61
31617171 2020
42
[Genital herpes simplex virus infection in pregnancy]. 61
32052736 2020
43
Aberrant cervical innate immunity predicts onset of dysbiosis and sexually transmitted infections in women of reproductive age. 61
31914129 2020
44
Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis. 61
32027675 2020
45
The association between region of birth and sexually transmitted infections among people of black Caribbean ethnicity attending sexual health services in England, 2015. 61
32084155 2020
46
Estimating nationwide cases of sexually transmitted diseases in 2015 from sentinel surveillance data in Japan. 61
31992256 2020
47
Transcriptional Regulation of Latency-Associated Transcripts (LATs) of Herpes Simplex Viruses. 61
32231745 2020
48
Genital Infection With Herpes Simplex Virus Type 1 and Type 2 in Valencia, Spain: A Retrospective Observational Study. 61
31744595 2020
49
Frequent Recurrences of Genital Herpes Are Associated with Enhanced Systemic HSV-Specific T Cell Response. 61
32047574 2020
50
Oral Transmission of Sexually Transmissable Infections: A Narrative Review. 61
31851887 2019
51
Time Trends in First-Episode Genital Herpes Simplex Virus Infections in an Urban Sexually Transmitted Disease Clinic. 61
31764767 2019
52
Maintaining Breastfeeding During Severe Infant and Maternal HSV-1 Infection: A Case Report. 61
30840531 2019
53
Granzyme B Cleaves Multiple Herpes Simplex Virus 1 and Varicella-Zoster Virus (VZV) Gene Products, and VZV ORF4 Inhibits Natural Killer Cell Cytotoxicity. 61
31462576 2019
54
[Acute genital ulcers in a young woman]. 61
31769629 2019
55
Herpetiform aphthous genital ulcers misdiagnosed as herpes genitalis in a young male and their effective response to colchicine therapy. 61
31775589 2019
56
Depot-medroxyprogesterone acetate reduces genital cell-cell adhesion molecule expression and increases genital herpes simplex virus type 2 infection susceptibility in a dose-dependent fashion. 61
31302121 2019
57
Different solid forms for optimizing route of administration of the herpes drug Pritelivir. 61
32346467 2019
58
Successful sofosbuvir lead-in monotherapy for the treatment of hepatitis C virus (HCV) infection in a pregnant woman living with HIV. 61
31645394 2019
59
Data-driven queries between medications and spontaneous preterm birth among 2.5 million pregnancies. 61
31433567 2019
60
Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes. 61
31515143 2019
61
Recurrent herpes labialis and Herpes simplex virus-1 genitalis: what is the link? 61
28181784 2019
62
Time Trends in First Episode Genital Herpes Simplex Virus Infections in an Urban STD Clinic. 61
31688723 2019
63
Herpes simplex virus type 1 epidemiology in Africa: Systematic review, meta-analyses, and meta-regressions. 61
31376458 2019
64
Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes. 61
31541030 2019
65
Contriving a chimeric polyvalent vaccine to prevent infections caused by herpes simplex virus (type-1 and type-2): an exploratory immunoinformatic approach. 61
31328668 2019
66
A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection. 61
31058977 2019
67
A Case of Dermatitis Herpetiformis With Fibrillar Immunoglobulin A Deposition: A Rare Pattern Not to Be Missed. 61
30839342 2019
68
Sacral Myeloradiculitis: An Uncommon Complication of Genital Herpes Infection. 61
31217310 2019
69
Migrant memory B cells secrete luminal antibody in the vagina. 61
31189952 2019
70
Atypical Presentation of Herpes Simplex Virus Type 2 Infection Refractory to Treatment With Aciclovir in 2 Hematologic Patients. 61
29203034 2019
71
Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease. 61
31103365 2019
72
Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants. 61
31153687 2019
73
Sexually Transmitted Diseases in the Emergency Department. 61
30940365 2019
74
Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4+ and CD8+ TRM Cells Associated with Protection against Recurrent Genital Herpes. 61
30787156 2019
75
18F-FDG PET/CT Findings in Disseminated Genital Herpes in an Immunocompetent Patient With Anaplastic Lymphoma Kinase Rearranged Advanced Nonsmall Cell Lung Cancer. 61
30829864 2019
76
[Cutaneous Herpesvirus Infection]. 61
30988211 2019
77
Genital ulcers caused by herpes simplex virus. 61
30580877 2019
78
Sexually transmitted infections, active component, U.S. Armed Forces, 2010-2018. 61
30912663 2019
79
Vegetative chronic genital herpes with satisfactory response to imiquimod. 61
31090830 2019
80
Signs heralding appearance of thymomas after extended thymectomy for myasthenia gravis. 61
30859007 2019
81
Expression of Concern to: Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases. 61
30725243 2019
82
A merged molecular docking, ADME-T and dynamics approaches towards the genus of Arisaema as herpes simplex virus type 1 and type 2 inhibitors. 61
30579134 2019
83
The Epidemiology of Herpes Simplex Virus Type 1 in Asia: Systematic Review, Meta-analyses, and Meta-regressions. 61
30020453 2019
84
The Effect of Aloe Vera Clinical Trials on Prevention and Healing of Skin Wound: A Systematic Review. 61
30666070 2019
85
Association of abnormal cervical cytology with coinfection of human papillomavirus and Chlamydia trachomatis. 61
31143862 2019
86
Herpes Simplex Virus Type 2 Radiculomyelitis Disguised as Conversion Disorder. 61
31543792 2019
87
Duration of protection from live attenuated vs. sub unit HSV-2 vaccines in the guinea pig model of genital herpes: Reassessing efficacy using endpoints from clinical trials. 61
30917165 2019
88
The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes. 61
30471955 2019
89
Hampering Herpesviruses HHV-1 and HHV-2 Infection by Extract of Ginkgo biloba (EGb) and Its Phytochemical Constituents. 61
31681227 2019
90
HSV-2 Cellular Programming Enables Productive HIV Infection in Dendritic Cells. 61
31867020 2019
91
Extensive vulval and perianal ulceration due to genital herpes virus infection. 61
31143869 2019
92
[Diagnostic and therapeutic recommendations for sexually transmitted diseases: Genital herpes]. 61
30366717 2019
93
Antiviral Properties of R. tanguticum Nanoparticles on Herpes Simplex Virus Type I In Vitro and In Vivo. 61
31555137 2019
94
Herpes simplex virus type 1 epidemiology in Latin America and the Caribbean: Systematic review and meta-analytics. 61
31009486 2019
95
The Effect of Hormonal Contraception and Menstrual Cycle Timing on Genital Herpes Simplex Virus-2 Shedding and Lesions. 61
30148758 2019
96
Herpes Simplex Virus Type 2 Immediate Early Protein ICP27 Inhibits IFN-β Production in Mucosal Epithelial Cells by Antagonizing IRF3 Activation. 61
30863402 2019
97
A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection. 61
30551986 2019
98
Behavioral, Psychological, Gender, and Health Service Correlates to Herpes Simplex Virus Type 2 Infection among Young Adult Mexican-American Women Living in a Disadvantaged Community. 61
29558260 2019
99
In vitro and in vivo anti-herpes simplex virus activity of monogalactosyl diacylglyceride from Coccomyxa sp. KJ (IPOD FERM BP-22254), a green microalga. 61
31310628 2019
100
Genital Herpes Zoster as Possible Indicator of HIV Infection. 61
30665486 2018
101
Immuno-metabolic changes in herpes virus infection. 61
29960669 2018
102
Prospective cohort study showing persistent HSV-2 shedding in women with genital herpes 2 years after acquisition. 61
29175899 2018
103
Comparison of Acyclovir and Multistrain Lactobacillus brevis in Women with Recurrent Genital Herpes Infections: a Double-Blind, Randomized, Controlled Study. 61
28852985 2018
104
Disease Pattern among Sexually Transmitted Infection Clinic Attendees: A Hospital-Based Study. 61
30504980 2018
105
Increase in HSV shedding at initiation of antiretroviral therapy and decrease in shedding over time on antiretroviral therapy in HIV and HSV-2 infected persons. 61
30289810 2018
106
Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital Herpes Simplex Virus-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-Controlled Trial. 61
29982727 2018
107
Herpes Simplex Virus 1 and 2 in Herpes Genitalis: A Polymerase Chain Reaction-Based Study from Kerala. 61
30504975 2018
108
Longitudinal association of gonorrhea and bacterial vaginosis with repeat chlamydia diagnoses among U.S. Army women: a retrospective cohort analysis. 61
30373657 2018
109
ACOG Committee Opinion No. 754 Summary: The Utility of and Indications for Routine Pelvic Examination. 61
30247359 2018
110
ACOG Committee Opinion No. 754: The Utility of and Indications for Routine Pelvic Examination. 61
30247363 2018
111
Evaluation of an Integrated Cell Culture-based and PCR Assay for Diagnosis of Genital Herpes in Women. 61
30390721 2018
112
Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals. 61
30020484 2018
113
Antiviral Activity of Tannic Acid Modified Silver Nanoparticles: Potential to Activate Immune Response in Herpes Genitalis. 61
30261662 2018
114
Interferon epsilon in the reproductive tract of healthy and genital herpes simplex virus-infected pregnant women: Results of a pilot study. 61
29905034 2018
115
Surgical excision of a large, verrucous, scrotal mass in a patient with HSV-2 and HIV-1 co-infection. 61
29988734 2018
116
In Vivo Knockdown of the Herpes Simplex Virus 1 Latency-Associated Transcript Reduces Reactivation from Latency. 61
29875240 2018
117
Addressing the Increased Incidence of Common Sexually Transmitted Infections. 61
30073343 2018
118
Women infected with HIV and the impact of associated sexually transmitted infections. 61
29656416 2018
119
Should Caesarian Section Be Offered to Women With Recurrent Genital Herpes Simplex Lesions After >4 Hours of Ruptured Membranes? 61
30103879 2018
120
Update on Neonatal Herpes Simplex Epidemiology in the Netherlands: A Health Problem of Increasing Concern? 61
29356762 2018
121
Quality of life and depression in chronic sexually transmitted infections in UK and Greece: The use of WHOQOL-HIV/STI BREF. 61
30605425 2018
122
Viral Hypothesis and Antiviral Treatment in Alzheimer's Disease. 61
30008124 2018
123
Genome-Wide Surveillance of Genital Herpes Simplex Virus Type 1 From Multiple Anatomic Sites Over Time. 61
29920588 2018
124
Cost of Routine Herpes Simplex Virus Infection Visits to U.S. Emergency Departments 2006-2013. 61
30013705 2018
125
Antiviral Effect of Retro-2.1 against Herpes Simplex Virus Type 2 In Vitro. 61
29847864 2018
126
Proteflazid®: treatment of herpesvirus and mixed infections. Meta-analysis of clinical trials results. 61
29813042 2018
127
Health-related quality of life of young people and adults with primary or recurrent episodes of genital herpes: a mixed methods systematic review protocol. 61
29762300 2018
128
Transcriptional Analysis of the Guinea Pig Mucosal Immune Response to Intravaginal Infection with Herpes Simplex Virus Type 2. 61
29604476 2018
129
Prevention and management of genital herpes simplex infection during pregnancy and delivery: Guidelines from the French College of Gynaecologists and Obstetricians (CNGOF). 61
29571124 2018
130
[Genital herpes]. 61
29798750 2018
131
CXCL17 Chemokine-Dependent Mobilization of CXCR8+CD8+ Effector Memory and Tissue-Resident Memory T Cells in the Vaginal Mucosa Is Associated with Protection against Genital Herpes. 61
29549178 2018
132
STING agonists enable antiviral cross-talk between human cells and confer protection against genital herpes in mice. 61
29608601 2018
133
Laser Adjuvant-Assisted Peptide Vaccine Promotes Skin Mobilization of Dendritic Cells and Enhances Protective CD8+ TEM and TRM Cell Responses against Herpesvirus Infection and Disease. 61
29437976 2018
134
Self-reported minor infections in patients with hidradenitis suppurativa and healthy controls. 61
28994129 2018
135
A case of hypertrophic herpes simplex virus affecting the eyelid and cornea masquerading as IgG4-related disease. 61
29468223 2018
136
Co-infection of human herpesvirus type 2 (HHV-2) and human immunodeficiency virus (HIV) among pregnant women in Rio de Janeiro, Brazil. 61
28914079 2018
137
Antiviral Effects of ABMA against Herpes Simplex Virus Type 2 In Vitro and In Vivo. 61
29522484 2018
138
The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase. 61
29186456 2018
139
Genital herpes stigma: Toward the Measurement and Validation of a highly prevalent yet hidden public health problem. 61
29629409 2018
140
A Case-Control Study in Primary Care Settings on the Roles of Dermatoscopy in Infectious Diseases Affecting the Skin, Part 1: Viral and Bacterial Infections. 61
30207527 2018
141
The first case of lymphogranuloma venereum in a woman in East-Central Europe and its multiple co-infections. 61
28741042 2018
142
The Etiology of Genital Ulcer Disease and Coinfections With Chlamydia trachomatis and Neisseria gonorrhoeae in Zimbabwe: Results From the Zimbabwe STI Etiology Study. 61
29240636 2018
143
The Role of Polymorphonuclear Leukocyte Counts from Urethra, Cervix, and Vaginal Wet Mount in Diagnosis of Nongonococcal Lower Genital Tract Infection. 61
30147292 2018
144
[Clinical, epidemiological, and etiological studies of adult aseptic meningitis: a report of 12 cases of herpes simplex meningitis, and a comparison with cases of herpes simplex encephalitis]. 61
29269697 2018
145
Exogenous oestrogen inhibits genital transmission of cell-associated HIV-1 in DMPA-treated humanized mice. 61
29334191 2018
146
CONCOMITANT SEXUALLY TRANSMITTED DISEASES IN PATIENTS WITH DIAGNOSED HIV/AIDS: A RETROSPECTIVE STUDY. 61
29619436 2018
147
Antiviral Drugs Against Alphaherpesvirus. 61
29896665 2018
148
[Erratum to "Management of pregnant women with first episode of genital herpes. Guidelines for clinical practice from the French college of gynecologists and obstetricians (CNGOF)" [Gynecol Obstet Fertil Senol. 45 (2017) 664-76]]. 61
29274775 2018
149
Anti HSV-2 activity of Peganum harmala (L.) and isolation of the active compound. 61
29223449 2018
150
Hyperosmolal vaginal lubricants markedly reduce epithelial barrier properties in a three-dimensional vaginal epithelium model. 61
29854584 2018
151
Clinical Trial of Herbal Treatment Gene-Eden-VIR/Novirin in Oral Herpes. 61
30362389 2018
152
Intramuscular delivery of replication-defective herpes simplex virus gives antigen expression in muscle syncytia and improved protection against pathogenic HSV-2 strains. 61
29069622 2018
153
The Ticking CLOCK of HSV-2 Pathology. 61
29273146 2018
154
A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model. 61
28481687 2017
155
Primary syphilis in pregnancy mistaken for genital herpes: A preventable cause of congenital syphilis. 61
29103618 2017
156
The alpha-herpesviridae in dermatology : Herpes simplex virus types I and II. 61
28197698 2017
157
Media Consumption and Creation in Attitudes Toward and Knowledge of Inflammatory Bowel Disease: Web-Based Survey. 61
29222081 2017
158
[Genital herpes and pregnancy: Epidemiology, clinical manifestations, prevention and screening. Guidelines for clinical practice from the French College of Gynecologists and Obstetrician (CNGOF)]. 61
29146286 2017
159
[Neonatal herpes: Epidemiology, clinical manifestations and management. Guidelines for clinical practice from the French College of Gynecologists and Obstetricians (CNGOF)]. 61
29132771 2017
160
Clinacanthus nutans: a review on ethnomedicinal uses, chemical constituents and pharmacological properties. 61
28198202 2017
161
[Management of pregnant women with recurrent herpes. Guidelines for clinical practice from the French College of Gynecologists, Obstetricians (CNGOF)]. 61
29132770 2017
162
[Management of pregnant women with first episode of genital herpes. Guidelines for clinical practice from the French college of gynecologists and obstetricians (CNGOF)]. 61
29132767 2017
163
[Genital herpes and pregnancy: Serological and molecular diagnostic tools. Guidelines for clinical practice from the French College of Gynecologists and Obstetricians (CNGOF)]. 61
29132769 2017
164
2017 European guidelines for the management of genital herpes. 61
28836892 2017
165
Dual-strain genital herpes simplex virus type 2 (HSV-2) infection in the US, Peru, and 8 countries in sub-Saharan Africa: A nested cross-sectional viral genotyping study. 61
29281620 2017
166
Pregnancy Outcomes in Association with STDs including genital HSV-2 shedding in a South African Cohort Study. 61
28396556 2017
167
Helicase-primase inhibitor amenamevir for herpesvirus infection: Towards practical application for treating herpes zoster. 61
29451274 2017
168
Characterization of Inherent Particles and Mechanism of Thermal Stress Induced Particle Formation in HSV-2 Viral Vaccine Candidate. 61
28914197 2017
169
A case of MOG antibody-positive bilateral optic neuritis and meningoganglionitis following a genital herpes simplex virus infection. 61
29055448 2017
170
Sexually transmitted infection prevalence and related risk factors among heterosexual male methamphetamine users in China. 61
28178893 2017
171
Skin diseases of the vulva: Infectious diseases. 61
28397528 2017
172
Cutting Edge: Genetic Association between IFI16 Single Nucleotide Polymorphisms and Resistance to Genital Herpes Correlates with IFI16 Expression Levels and HSV-2-Induced IFN-β Expression. 61
28893956 2017
173
A high resolution melting (HRM) technology-based assay for cost-efficient clinical detection and genotyping of herpes simplex virus (HSV)-1 and HSV-2. 61
28734843 2017
174
Differential expression of mRNA and miRNA in guinea pigs following infection with HSV2v. 61
28962197 2017
175
Genital herpes. 61
28619732 2017
176
Skin diseases of the male external genitalia in the Tanlangai Hospital in Brazzaville, Congo. 61
28947407 2017
177
Genital Herpes Infection in an Adolescent with Diabetes Mellitus. 61
28891491 2017
178
No. 208-Guidelines for the Management of Herpes Simplex Virus in Pregnancy. 61
28729112 2017
179
A model of genital herpes simplex virus Type 1 infection in Rhesus Macaques. 61
28748667 2017
180
Lifetime Sexual Assault and Sexually Transmitted Infections Among Women Veterans. 61
28281918 2017
181
Potential risk of developing herpes simplex encephalitis in patients treated with sildenafil following primary exposure to genital herpes. 61
28956417 2017
182
Correlating CD4 count with mucocutaneous manifestations in HIV-positive patients: A prospective study. 61
30148265 2017
183
No. 207-Genital Herpes: Gynaecological Aspects. 61
28625289 2017
184
A retrospective study of the pattern of sexually transmitted infections from a tertiary care hospital of Rajasthan. 61
30148268 2017
185
Prevalence of herpes simplex virus types 1 and 2 at maternal and fetal sides of the placenta in asymptomatic pregnant women. 61
28440579 2017
186
Herpes simplex virus: 'to disclose or not to disclose.' An exploration of the multi-disciplinary team's role in advising patients about disclosure when diagnosed with genital herpes simplex virus. 61
27582307 2017
187
Serologic Screening for Genital Herpes Infection: Recommendation Statement. 61
28671418 2017
188
Serologic Screening for Genital Herpes Infection. 61
28671417 2017
189
Global sensing of the antigenic structure of herpes simplex virus gD using high-throughput array-based SPR imaging. 61
28614387 2017
190
The Product of the Herpes Simplex Virus 2 UL16 Gene Is Critical for the Egress of Capsids from the Nuclei of Infected Cells. 61
28275195 2017
191
Herpes simplex virus specific T cell response in a cohort with primary genital infection correlates inversely with frequency of subsequent recurrences. 61
27903680 2017
192
Recalcitrant hypertrophic herpes genitalis in HIV-infected patient successfully treated with topical imiquimod. 61
28261899 2017
193
Dorsal longitudinal foreskin cut is associated with reduced risk of HIV, syphilis and genital herpes in men: a cross-sectional study in Papua New Guinea. 61
28406272 2017
194
NK cells require antigen-specific memory CD4+ T cells to mediate superior effector functions during HSV-2 recall responses in vitro. 61
27974365 2017
195
Periodic Screening Pelvic Examination: Evidence Report and Systematic Review for the US Preventive Services Task Force. 61
28267861 2017
196
PARTNER NOTIFICATION OUTCOMES AMONG MALE GONORRHEA PATIENTS AT BANGRAK HOSPITAL, BANGKOK, THAILAND. 61
29642299 2017
197
Sexual health of women aged 40 and over attending an inner city integrated sexual health clinic. 61
28198339 2017
198
Proteflazid® and local immunity in diseases caused by human papillomavirus, herpesvirus and mixed urogenital infections. 61
28333902 2017
199
[The alpha-herpesviridae in dermatology : Herpes simplex virus types I and II. German version]. 61
28197699 2017
200
Extensive and refractory genital herpes in human immunodeficiency virus-infected patient successfully treated with imiquimod: Case report and literature review. 61
28164895 2017
201
Screening for Genital Herpes: What Is Not to Be Done. 61
27997634 2017
202
Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial. 61
28329211 2017
203
Epidemiological aspects of genital ulcers at the STI center of the National Institute of Public Hygiene (Abidjan, Côte d'Ivoire) 2008 to 2010. 61
28406423 2017
204
External Use of Propolis for Oral, Skin, and Genital Diseases: A Systematic Review and Meta-Analysis. 61
28265293 2017
205
Antiviral Medication in Sexually Transmitted Diseases. Part III: Hepatitis B, Hepatitis C. 61
27515715 2017
206
Sexual Lifestyle, Risk Factors and Socioeconomic Status of the STD Patients in Bangladesh. 61
28260751 2017
207
Development of Recombinant HSV-Based Vaccine Vectors. 61
28374243 2017
208
Clinico-epidemiological profile of patients attending Suraksha Clinic of tertiary care hospital of North India. 61
28442804 2017
209
[Endometrial dysfunction caused by chronic endometritis: сlinical and morphological aspects]. 61
29265074 2017
210
First-episode genital herpes: interventions for men and women. 61
28120659 2017
211
A Comparative Analysis of Polymerase Chain Reaction and Direct Fluorescent Antibody Test for Diagnosis of Genital Herpes. 61
28042218 2017
212
Mechanistic Studies of Viral Entry: An Overview of Dendrimer-Based Microbicides As Entry Inhibitors Against Both HIV and HSV-2 Overlapped Infections. 61
27518199 2017
213
An HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs. 61
28103319 2017
214
Herpes simplex virus 1 and 2 educational assessment of young adults in rural southwest Virginia. 61
28654651 2017
215
Invasive Obstetric Procedures and Cesarean Sections in Women With Known Herpes Simplex Virus Status During Pregnancy. 61
29308404 2017
216
Leflunomide in the Treatment of a Pseudotumoral Genital Herpes Simplex Virus Infection in an HIV Patient. 61
28373917 2017
217
The Characteristics of Herpes Simplex Virus Type 1 Infection in Rhesus Macaques and the Associated Pathological Features. 61
28146109 2017
218
Tuberculosis of Glans Penis- A Rare Presentation. 61
28208927 2016
219
Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells. 61
27407095 2016
220
Sexual temptation: substance abuse, no sex, safe sex, risky sex, and STDs. 61
28009539 2016
221
HLA Class I and II alleles, heterozygosity and HLA-KIR interactions are associated with rates of genital HSV shedding and lesions. 61
27853144 2016
222
Serologic Screening for Genital Herpes: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. 61
27997660 2016
223
Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases. 61
27766602 2016
224
JAMA patient page: Screening for Genital Herpes. 61
27997655 2016
225
A Recommendation Against Serologic Screening for Genital Herpes Infection-What Now? 61
27997636 2016
226
Serologic Screening for Genital Herpes Infection: US Preventive Services Task Force Recommendation Statement. 61
27997659 2016
227
Herpes Genitalis: Diagnosis, Treatment and Prevention. 61
28017972 2016
228
Characterization of Vesicular Stomatitis Virus Pseudotypes Bearing Essential Entry Glycoproteins gB, gD, gH, and gL of Herpes Simplex Virus 1. 61
27605677 2016
229
Examining the role of socioeconomic deprivation in ethnic differences in sexually transmitted infection diagnosis rates in England: evidence from surveillance data. 61
27511704 2016
230
[Interferon in combined therapy of human papillomavirus infections associated with sexually transmitted infections. linical observation]. 61
28248030 2016
231
Herpes simplex virus type 2-associated recurrent aseptic meningitis (Mollaret's meningitis) with a recurrence after 11-year interval: a case report. 61
27773908 2016
232
[Genital herpes]. 61
27771124 2016
233
Genital Herpes. 61
27959656 2016
234
Genital Herpes. 61
27959657 2016
235
Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection. 61
27007679 2016
236
Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. 61
27733282 2016
237
Associations between individual and relationship characteristics and genital herpes disclosure. 61
25814164 2016
238
Two cases of genital neutrophilic sebaceous adenitis. 61
27178726 2016
239
Heterogeneous polymer composite nanoparticles loaded in situ gel for controlled release intra-vaginal therapy of genital herpes. 61
27351137 2016
240
Prevalence and associated factors of behavioral intention for risk compensation following voluntary medical male circumcision among male sexually transmitted diseases patients in China. 61
27120407 2016
241
Cesarean Delivery in Adolescents. 61
26836505 2016
242
Association of Depressed Mood With Herpes Simplex Virus-2 Immunoglobulin-G Levels in Pregnancy. 61
27490851 2016
243
Sexually transmitted infections and HIV in self reporting men who have sex with men: A two-year study from India. 61
26776704 2016
244
Metastastic vulvar squamous cell carcinoma mimicking genital herpes. 61
27752532 2016
245
Sexually Transmitted Infections Among Hospitalized Patients With Human Immunodeficiency Virus Infection and Acquired Immune Deficiency Syndrome (HIV/AIDS) in Zahedan, Southeastern Iran. 61
27818966 2016
246
HSV-2 glycoprotein gD targets the CC domain of tetherin and promotes tetherin degradation via lysosomal pathway. 61
27630089 2016
247
Attitudes and Willingness to Assume Risk of Experimental Therapy to Eradicate Genital Herpes Simplex Virus Infection. 61
27513383 2016
248
Interventions for men and women with their first episode of genital herpes. 61
27575957 2016
249
Sexually transmitted infections case notification rates in the Kingdom of Saudi Arabia, 2005-2012. 61
27580336 2016
250
Functional prediction of differentially expressed lncRNAs in HSV-1 infected human foreskin fibroblasts. 61
27496175 2016
251
CLINICAL PRACTICE. Genital Herpes. 61
27532832 2016
252
Integrative pharmacokinetic-pharmacodynamic modeling and simulation of amenamevir (ASP2151) for treatment of recurrent genital herpes. 61
27461507 2016
253
Secreted herpes simplex virus-2 glycoprotein G alters thermal pain sensitivity by modifying NGF effects on TRPV1. 61
27576911 2016
254
Herpes simplex virus type 1 and type 2 in the Netherlands: seroprevalence, risk factors and changes during a 12-year period. 61
27484304 2016
255
Genital herpes. 61
27109044 2016
256
Role of type-specific herpes simplex virus-1 and 2 serology as a diagnostic modality in patients with clinically suspected genital herpes: A comparative study in Indian population from a tertiary care hospital. 61
27510668 2016
257
In Situ Detection of Regulatory T Cells in Human Genital Herpes Simplex Virus Type 2 (HSV-2) Reactivation and Their Influence on Spontaneous HSV-2 Reactivation. 61
27117511 2016
258
Collaboration with a midwife in the care of a pregnant patient with recurrent genital herpes simplex virus. 61
27412208 2016
259
CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections. 61
27362483 2016
260
Viral Spread to Enteric Neurons Links Genital HSV-1 Infection to Toxic Megacolon and Lethality. 61
27281569 2016
261
Intravaginal Zinc Oxide Tetrapod Nanoparticles as Novel Immunoprotective Agents against Genital Herpes. 61
27183601 2016
262
Genital Herpes: A Review. 61
27281837 2016
263
Genital Herpes: What You Should Know. 61
27281843 2016
264
Genital Herpes: Insights into Sexually Transmitted Infectious Disease. 61
28357380 2016
265
Subclinical generation of acyclovir-resistant herpes simplex virus with mutation of homopolymeric guanosine strings during acyclovir therapy. 61
26917345 2016
266
HSV antivirals - current and future treatment options. 61
26897058 2016
267
False-negative type-specific glycoprotein G antibody responses in STI clinic patients with recurrent HSV-1 or HSV-2 DNA positive genital herpes, The Netherlands. 61
26755775 2016
268
First HSV-1 non primary genital herpes in two patients. 61
27018573 2016
269
Access of protective antiviral antibody to neuronal tissues requires CD4 T-cell help. 61
27225131 2016
270
[Construction and Immunogenicity Analysis of Herpes Simplex Virus Type 2 Glycoprotein D Recombinant Adenovirus Vaccine]. 61
29962197 2016
271
Effects of a traditional Chinese medicine, Longdanxiegan formula granule, on Toll-like receptor pathway in female guinea pigs with recurrent genital herpes. 61
27125405 2016
272
Evolution of rational vaccine designs for genital herpes immunotherapy. 61
26896782 2016
273
Coping strategies and behavioural changes following a genital herpes diagnosis among an urban sample of underserved Midwestern women. 61
25792549 2016
274
Seroprevalence and risk factors of herpes simplex virus-2 among pregnant women attending antenatal care at health facilities in Wolaita zone, Ethiopia. 61
26979484 2016
275
Sexually transmitted infections in U.S. Air Force recruits in basic military training. 61
26930147 2016
276
Polish consensus guidelines on the use of acyclovir in the treatment and prevention of VZV and HSV infections. 61
26643900 2016
277
The Basic Domain of Herpes Simplex Virus 1 pUS9 Recruits Kinesin-1 To Facilitate Egress from Neurons. 61
26656703 2016
278
Potential impact of the human papillomavirus vaccine on the incidence proportion of genital warts in French women (EFFICAE study): a multicentric prospective observational study. 61
26567557 2016
279
Stunting at 5 Years Among SGA Newborns. 61
26772663 2016
280
Predictors of the Sexual Well-being of Individuals Diagnosed with Herpes and Human Papillomavirus. 61
25408498 2016
281
Unfortunate synergy between HIV and genital herpes. 61
26884529 2016
282
Does suppressive antiviral therapy for herpes simplex virus prevent transmission in an HIV-positive population? A systematic review. 61
29770002 2016
283
Genital Herpes Simplex Virus Type 2 Shedding Among Adults With and Without HIV Infection in Uganda. 61
26486633 2016
284
Herpes Simplex Virus-2 Esophagitis in a Young Immunocompetent Adult. 61
27195158 2016
285
Self-reported sexually transmitted infections among female university students. 61
26489857 2016
286
Characteristics of Sexually Transmitted Infections among High-Risk HIV-Positive Patients Attending an Urban Clinic in Uganda. 61
24144639 2016
287
First description of herpes simplex virus type 1 epididymo-orchitis: A new clinical form of herpes simplex virus infection during septic shock? 61
27672563 2016
288
A Retrospective Study of the Pattern of Sexually Transmitted Infections in Males: Viral Infections in Emerging Trend. 61
26894160 2016
289
Non-healing genital herpes mimicking donovanosis in an immunocompetent man. 61
25614521 2016
290
Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovir. 61
27621592 2016
291
Nasal Immunization Confers High Avidity Neutralizing Antibody Response and Immunity to Primary and Recurrent Genital Herpes in Guinea Pigs. 61
28082979 2016
292
Herpes simplex virus seroprevalence and seroconversion among active duty US air force members with HIV infection. 61
26615389 2016
293
Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding. 61
26561565 2016
294
OASL1 deficiency promotes antiviral protection against genital herpes simplex virus type 2 infection by enhancing type I interferon production. 61
26750802 2016
295
The occurrence of herpes simplex viruses 1 and 2 in skin and mucosal lesions in patients with suspicion of genital herpes. 61
28146623 2016
296
Herpes Simplex Virus 1 Infection of Tree Shrews Differs from That of Mice in the Severity of Acute Infection and Viral Transcription in the Peripheral Nervous System. 61
26512084 2016
297
Optimal management of genital herpes: current perspectives. 61
27358569 2016
298
A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2. 61
26559846 2016
299
Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus. 61
26609935 2016
300
Successful treatment of hypertrophic herpes simplex genitalis in HIV-infected patient with topical imiquimod. 61
26074211 2015
301
Updating the management of sexually transmitted infections. 61
26843713 2015
302
Oral and Vaginal Tenofovir for Genital Herpes Simplex Virus Type 2 Shedding in Immunocompetent Women: A Double-Blind, Randomized, Cross-over Trial. 61
26044291 2015
303
High Rate of β-Globin DNA Detection Validates Self-Sampling in Herpes Simplex Virus Shedding Studies. 61
26562701 2015
304
Valaciclovir versus aciclovir for the treatment of primary genital herpes simplex: a cost analysis. 61
25505043 2015
305
Harmine blocks herpes simplex virus infection through downregulating cellular NF-κB and MAPK pathways induced by oxidative stress. 61
26348003 2015
306
Patient Preferences for Test Result Notification. 61
25944020 2015
307
Expression and characterization of the gD protein of HSV-2 fused to the tetramerization domain of the transcription factor p53. 61
26209556 2015
308
[Contribution of Electronic Health Record in Surveillance of Notifiable Diseases]. 61
26650475 2015
309
Intravenous Foscarnet With Topical Cidofovir for Chronic Refractory Genital Herpes in a Patient With AIDS. 61
26788527 2015
310
Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model. 61
26178984 2015
311
Erratum to: Diagnosis of genital herpes simplex virus infection in the clinical laboratory. 61
26463442 2015
312
The Contribution of Cervicovaginal Infections to the Immunomodulatory Effects of Hormonal Contraception. 61
26330510 2015
313
Variability of human immunodeficiency virus-1 in the female genital reservoir during genital reactivation of herpes simplex virus type 2. 61
26003280 2015
314
Seroprevalence of Herpes Simplex Virus Type 1 and Type 2 and Coinfection With HIV and Syphilis: The First National Seroprevalence Survey in Saudi Arabia. 61
26267880 2015
315
Sexually Transmitted Diseases as a Risk for Acquiring HIV Infection among the Population of Men Who Have Sex with Men--A Case-Control Study. 61
26898074 2015
316
Contribution of N-linked glycans on HSV-2 gB to cell-cell fusion and viral entry. 61
25965797 2015
317
The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment. 61
26157126 2015
318
Chitosan and Kappa-Carrageenan Vaginal Acyclovir Formulations for Prevention of Genital Herpes. In Vitro and Ex Vivo Evaluation. 61
26393621 2015
319
An age-structured model for the coupled dynamics of HIV and HSV-2. 61
25974346 2015
320
A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens. 61
26041292 2015
321
Genome Sequencing and Analysis of Geographically Diverse Clinical Isolates of Herpes Simplex Virus 2. 61
26018166 2015
322
Syphilis: Is it making resurgence? 61
26692612 2015
323
[TREATMENT OF PATIENTS WITH CHRONIC RECURRENT HERPES VIRUS INFECTION OF GENITAL LOCALIZATION: A CLINICAL STUDY OF FORTEPREN PREPARATION]. 61
26470430 2015
324
Study of patterns of sexually transmitted diseases using a syndromic approach in the era of human immunodeficiency virus from a tertiary care hospital of the Northern India. 61
26692608 2015
325
[VIRAL INFECTIONS: HUMAN PAPILLOMAVIRUS AND GENITAL HERPES TYPE 1 AND TYPE 2 AS A CAUSE OF CHRONIC RECURRENT CYSTITIS WITH SEVERE DYSURIA IN WOMEN WITH URETHRAL HYPERMOBILITY AND HYPOSPADIAS]. 61
26665761 2015
326
A model for the coupled disease dynamics of HIV and HSV-2 with mixing among and between genders. 61
25953482 2015
327
Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients. 61
25819042 2015
328
Production of a fragment of glycoprotein G of herpes simplex virus type 2 and evaluation of its diagnostic potential. 61
25532518 2015
329
Novel rat models to study primary genital herpes simplex virus-2 infection. 61
25701211 2015
330
Young people's comparative recognition and recall of an Australian Government Sexual Health Campaign. 61
25006041 2015
331
Socio-demographic and behavioural characteristics associated with HSV-2 sero-prevalence in high risk women in KwaZulu-Natal. 61
25940115 2015
332
Atypical presentations of genital herpes simplex virus in HIV-1 and HIV-2 effectively treated by imiquimod. 61
24912536 2015
333
Herpes simplex virus type 2-infected dendritic cells produce TNF-α, which enhances CCR5 expression and stimulates HIV production from adjacent infected cells. 61
25840914 2015
334
Molecular diagnostics and newborns at risk for genital herpes simplex virus. 61
25996200 2015
335
Neonatal herpes infections in The Netherlands in the period 2006-2011. 61
25014318 2015
336
HSV-2 immediate-early protein US1 inhibits IFN-β production by suppressing association of IRF-3 with IFN-β promoter. 61
25712217 2015
337
Genital herpes: oral antiviral treatments. 61
25853497 2015
338
Relay of herpes simplex virus between Langerhans cells and dermal dendritic cells in human skin. 61
25875649 2015
339
Neonatal herpes simplex virus infection: epidemiology and treatment. 61
25677996 2015
340
Sexually transmitted infection trends among gay or bisexual men from a clinic-based sentinel surveillance system in British Columbia, Canada. 61
25668648 2015
341
A 51-year-old man with seizures and progressive behavioral changes. 61
25732477 2015
342
Sexually transmitted diseases. 61
25565081 2015
343
Clinical inquiry: How well do antivirals shorten genital herpes pain duration? 61
25789347 2015
344
ACP Journal Club: review: oral antiviral drugs reduce clinical recurrence in recurrent genital herpes. 61
25686194 2015
345
Efficacy of N-methanocarbathymidine against genital herpes simplex virus type 2 shedding and infection in guinea pigs. 61
26149263 2015
346
Travel-related sexually transmitted infections. 61
26726895 2015
347
Pattern of sexually transmitted infections in a Muslim majority region of North India. 61
26392651 2015
348
Higher prevalence of sexual transmitted diseases and correlates of genital warts among heterosexual males attending sexually transmitted infection clinics (MSCs) in Jiangmen, China: implication for the up-taking of STD related service. 61
25811185 2015
349
Unusual initial presentation of herpes simplex virus as inguinal lymphadenopathy. 61
25815228 2015
350
Tuberculosis of the Penis: A Review of the Literature. 61
26435877 2015
351
Preparation and characterization of bioadhesive controlled-release gels of cidofovir for vaginal delivery. 61
26300445 2015
352
Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs. 61
25837802 2015
353
[Infections disease update: 2014 is viral]. 61
25799655 2015
354
Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways? 61
25787060 2015
355
History of venereal diseases from antiquity to the renaissance. 61
25969906 2015
356
Interferon Lambda 4 Genotype Is Not Associated with Recurrence of Oral or Genital Herpes. 61
26431156 2015
357
Antiviral medication in sexually transmitted diseases. Part II: HIV. 61
25751258 2015
358
[IMMUNOMODULATORS IN THE TREATMENT AND PREVENTION OF HERPES VIRUS INFECTIONS]. 61
26155705 2015
359
Seroprevalence of Herpes Simplex Virus Infection in HIV Coinfected Individuals in Eastern India with Risk Factor Analysis. 61
26557849 2015
360
Primary Genital Herpes Simplex Virus Type I in Preterm Prelabour Rupture of Membranes at 30 Weeks' Gestation. 61
26649212 2015
361
Herpes simplex virus 2 (HSV-2) infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine. 61
25658852 2015
362
Development and evaluation of the quantitative real-time PCR assay in detection and typing of herpes simplex virus in swab specimens from patients with genital herpes. 61
26770492 2015
363
Laboratory diagnosis and epidemiology of herpes simplex 1 and 2 genital infections. 61
26086165 2015
364
Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge. 61
25320297 2015
365
[Efficacy of polyprenyl phosphates in the experimental genital herpes model]. 61
26665428 2015
366
Human herpes simplex virus: life cycle and development of inhibitors. 61
25749169 2014
367
Herpes simplex virus infection during pregnancy. 61
25454993 2014
368
Preventing herpes simplex virus in the newborn. 61
25459782 2014
369
Prevalence of vulvodynia and risk factors for the condition in Portugal. 61
25092355 2014
370
Herpes simplex virus and cytomegalovirus co-infection presenting as exuberant genital ulcer in a woman infected with human immunodeficiency virus. 61
25250849 2014
371
Herpes genitalis and the philosopher's stance. 61
24429670 2014
372
Genital herpes and its treatment in relation to preterm delivery. 61
25392064 2014
373
Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D. 61
25138572 2014
374
The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine. 61
25446827 2014
375
Using a two-step method to measure transgender identity in Latin America/the Caribbean, Portugal, and Spain. 61
25030120 2014
376
[Epidemiological and clinical characteristics of anogenital dermatoses in the department of dermatology-venereology in Cotonou, Benin]. 61
25499900 2014
377
Pattern of sexually transmitted diseases in patients presenting at Ayub teaching hospital, Abbottabad. 61
25672192 2014
378
The increase of sexually transmitted infections calls for simultaneous preventive intervention for more effectively containing HIV epidemics in China. 61
25335839 2014
379
Age-related variation in sexual behaviours among heterosexual men residing in Brazil, Mexico and the USA. 61
24099979 2014
380
Development and clinical evaluation of a novel fully automated qualitative PCR assay for the diagnosis of anogenital herpes simplex virus infection. 61
25128985 2014
381
Genital herpes. 61
25153069 2014
382
A rare case of acyclovir-induced thrombocytopenia. 61
23344109 2014
383
Maternal genitourinary infections and the risk of gastroschisis. 61
25073472 2014
384
Engineering large viral DNA genomes using the CRISPR-Cas9 system. 61
25040500 2014
385
Mother-to-Child Transmission of Herpes Simplex Virus. 61
25232472 2014
386
Evaluation of the activity and safety of CS21 barrier genital gel® compared to topical aciclovir and placebo in symptoms of genital herpes recurrences: a randomized clinical trial. 61
24010876 2014
387
Statistical analysis of Amenamevir (ASP2151) between pharmacokinetics and clinical efficacies with non-linear effect model for the treatment of genital herpes. 61
27129009 2014
388
Sexual behavioral correlates with HSV-2 seroprevalence among pregnant women in Nigeria. 61
25116666 2014
389
Research gaps in defining the biological link between HIV risk and hormonal contraception. 61
24548147 2014
390
Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. 61
25086573 2014
391
Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine. 61
24798939 2014
392
Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes. 61
24829358 2014
393
Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine. 61
24652496 2014
394
Mimicking herpes simplex virus 1 and herpes simplex virus 2 mucosal behavior in a well-characterized human genital organ culture. 61
24436451 2014
395
Repertoire of epitopes recognized by serum IgG from humans vaccinated with herpes simplex virus 2 glycoprotein D. 61
24789783 2014
396
Status of prophylactic and therapeutic genital herpes vaccines. 61
24631871 2014
397
Acute herpetic gingivostomatitis associated with herpes simplex virus 2: report of a case. 61
25083042 2014
398
Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines? 61
24837838 2014
399
Diagnosis of genital herpes simplex virus infection in the clinical laboratory. 61
24885431 2014
400
Molecular and serologic diagnostic approaches; the prevalence of herpes simplex in idiopathic men infertile. 61
25031577 2014
401
Exemplars of complex assessment and care for hospitalized older adults: genital herpes infection. 61
24942524 2014
402
Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection. 61
24554666 2014
403
Epidemiology of genital herpes simplex virus type 1 and 2 infections in southwestern Finland during a 10-year period (2003-2012). 61
24622640 2014
404
Topical SMIP-7.7, a toll-like receptor 7 agonist, protects against genital herpes simplex virus type-2 disease in the guinea pig model of genital herpes. 61
23232327 2014
405
Increase male genital diseases morbidity linked to informal electronic waste recycling in Guiyu, China. 61
24271725 2014
406
The sexual health consultation as a moral occasion. 61
23336250 2014
407
Atypical presentation of genital herpes simplex (HSV-2) in two patients with chronic lymphocytic leukemia. 61
23975187 2014
408
Chancroid, lymphogranuloma venereum, granuloma inguinale, genital herpes simplex infection, and molluscum contagiosum. 61
24559566 2014
409
Sexual behaviors and sexually transmitted infections in a nationally representative sample of women veterans and nonveterans. 61
24328438 2014
410
Management rates of sexually transmissible infections by Australian general practitioners, 2000-2012. 61
24618039 2014
411
Youth violence and connectedness in adolescence: what are the implications for later sexually transmitted infections? 61
24268359 2014
412
Recommendations from international clinical guidelines for routine antenatal infection screening: does evidence matter? 61
24685900 2014
413
Current barriers, challenges and opportunities for the development of effective STI vaccines: point of view of vaccine producers, biotech companies and funding agencies. 61
23994377 2014
414
Vaccination with a HSV-2 UL24 mutant induces a protective immune response in murine and guinea pig vaginal infection models. 61
24462481 2014
415
Aneurysms of the Sinus of Valsalva in a Patient with Behcet's Disease. 61
25988099 2014
416
Topical application of polyethylenimine as a candidate for novel prophylactic therapeutics against genital herpes caused by herpes simplex virus. 61
24046087 2014
417
A paradigm shift: vaccine-induced antibodies as an immune correlate of protection against herpes simplex virus type 1 genital herpes. 61
24285847 2014
418
Herpes simplex virus: prevalence in placental tissue and incidence in neonatal cord blood samples. 61
24375504 2014
419
Herpes simplex virus type 1 genital herpes in young women: current trend in Northern Finland. 61
24431184 2014
420
Genital herpes simplex virus type 2 infection in humanized HIV-transgenic mice triggers HIV shedding and is associated with greater neurological disease. 61
23990571 2014
421
Cervicovaginal HIV-1 shedding in women taking antiretroviral therapy in Burkina Faso: a longitudinal study. 61
24226060 2014
422
Adolescents' and young women's use of a microbicide surrogate product when receiving oral sex. 61
24315715 2014
423
Current thinking on genital herpes. 61
24335720 2014
424
Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999-2010. 61
24136792 2014
425
Genomic sequences of a low passage herpes simplex virus 2 clinical isolate and its plaque-purified derivative strain. 61
24503076 2014
426
HSV-1 and HSV-2 seroprevalence in the united states among asymptomatic women unaware of any herpes simplex virus infection (Herpevac Trial for Women). 61
24926671 2014
427
Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs. 61
24284325 2014
428
Pediatric herpes simplex virus infections: an evidence-based approach to treatment. 61
24649621 2014
429
Prevalence of Trichomoniasis, Vaginal Candidiasis, Genital Herpes, Chlamydiasis, and Actinomycosis among Urban and Rural Women of Haryana, India. 61
26316979 2014
430
Reappraisal of sexually transmitted infections in children: A hospital-based study from an urban area. 61
24958982 2014
431
Tzanck smear utilized in the diagnosis of Hailey-Hailey disease mimicking genital herpes. 61
24117014 2014
432
[Cycloferon and management of herpes virus infection]. 61
25300118 2014
433
A clinico-epidemiological study of ulcerative sexually transmitted diseases with human immunodeficiency virus status. 61
24958991 2014
434
Herpes simplex virus type 2-associated recurrent aseptic (Mollaret's) meningitis in genitourinary medicine clinic: a case report. 61
24623993 2014
435
Prevalence of Anogenital Warts in Men with HIV/AIDS and Associated Factors. 61
25317220 2014
436
Decreased management of genital warts in young women in Australian general practice post introduction of national HPV vaccination program: results from a nationally representative cross-sectional general practice study. 61
25180698 2014
437
Comparison of risk factors for prevalent sexually transmitted infections based on attendees at two genitourinary medicine clinics in Ireland. 61
23970627 2014
438
Agenus‘ genital herpes vaccine significantly reduces viral burden in Phase 2. 61
25580483 2014
439
Helicase-primase inhibitor pritelivir for HSV-2 infection. 61
24428466 2014
440
Development of a novel approach to enhance the solubility of ftibamzone formulation. 61
26120473 2014
441
Effect of the potent antiviral 1-cinnamoyl-3,11-dihydroxymeliacarpin on cytokine production by murine macrophages stimulated with HSV-2. 61
23512754 2014
442
Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety. 61
24323471 2014
443
Asymptomatic memory CD8+ T cells: from development and regulation to consideration for human vaccines and immunotherapeutics. 61
24499824 2014
444
[A neonate with acute liver failure caused by herpes simplex infection]. 61
25248731 2014
445
Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial. 61
23850416 2013
446
Apparent Rarity of Asymptomatic Herpes Cervicitis in a Woman with Intra-Uterine Contraceptive Device. 61
28299103 2013
447
Understanding perceptions of genital herpes disclosure through analysis of an online video contest. 61
23702459 2013
448
Antiviral medication in sexually transmitted diseases. Part I: HSV, HPV. 61
24032509 2013
449
Application of shRNA-containing herpes simplex virus type 1 (HSV-1)-based gene therapy for HSV-2-induced genital herpes. 61
23845900 2013
450
Synthetic analogues of bovine bactenecin dodecapeptide reduce herpes simplex virus type 2 infectivity in mice. 61
24012999 2013
451
Trends in seroprevalence of herpes simplex virus type 2 among non-Hispanic blacks and non-Hispanic whites aged 14 to 49 years--United States, 1988 to 2010. 61
24113408 2013
452
[Syphilis. Part 1: Introduction, pathology and clinical aspects]. 61
24150827 2013
453
A not so simplex case of genital herpes. 61
24096072 2013
454
Novel deletion in glycoprotein G forms a cluster and causes epidemiologic spread of herpes simplex virus type 2 infection. 61
23861013 2013
455
Generating protective immunity against genital herpes. 61
24012144 2013
456
Genital warts in 250 Iranian patients and their high- risk sexual behaviors. 61
23981154 2013
457
Role of polymerase chain reaction in detection of genital herpes. 61
23974589 2013
458
Enhanced vaginal drug delivery through the use of hypotonic formulations that induce fluid uptake. 61
23769419 2013
459
Genital Herpes. 61
23910593 2013
460
Birth weight and other perinatal factors and childhood CNS tumors: a case-control study in California. 61
23562044 2013
461
Public health strategies for prevention and control of HSV-2 in persons who use drugs in the United States. 61
23647730 2013
462
Herpes simplex virus type 2 coinfection does not accelerate CD4 count decline in untreated HIV infection. 61
23572481 2013
463
Antiherpetic medication use and the risk of gastroschisis: findings from the National Birth Defects Prevention Study, 1997-2007. 61
23772935 2013
464
Sexually transmitted infections among patients with herpes simplex virus at King Abdulaziz University Hospital. 61
23898826 2013
465
Sexually transmitted diseases in a specialized STD healthcare center: epidemiology and demographic profile from January 1999 to December 2009. 61
24068122 2013
466
Antiviral activity of trappin-2 and elafin in vitro and in vivo against genital herpes. 61
23637403 2013
467
[Laboratory diagnosis of genital herpes--direct immunofluorescence method]. 61
24032273 2013
468
Exploiting herpes simplex virus entry for novel therapeutics. 61
23752649 2013
469
[Antibiotic profylaxis in obstetrics]. 61
23869838 2013
470
Griffithsin protects mice from genital herpes by preventing cell-to-cell spread. 61
23536670 2013
471
Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial. 61